WO2005056752A2 - Procedes et compositions permettant de distribuer des polynucleotides - Google Patents

Procedes et compositions permettant de distribuer des polynucleotides Download PDF

Info

Publication number
WO2005056752A2
WO2005056752A2 PCT/US2004/035137 US2004035137W WO2005056752A2 WO 2005056752 A2 WO2005056752 A2 WO 2005056752A2 US 2004035137 W US2004035137 W US 2004035137W WO 2005056752 A2 WO2005056752 A2 WO 2005056752A2
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotide
polypeptide
cell
protein
mitochondrial
Prior art date
Application number
PCT/US2004/035137
Other languages
English (en)
Other versions
WO2005056752A3 (fr
WO2005056752A9 (fr
Inventor
Shaharyar Khan
Original Assignee
Gencia Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gencia Corporation filed Critical Gencia Corporation
Priority to AU2004297533A priority Critical patent/AU2004297533B2/en
Priority to ES04817807T priority patent/ES2411962T3/es
Priority to JP2006536845A priority patent/JP4838722B2/ja
Priority to CA2543257A priority patent/CA2543257C/fr
Priority to EP04817807A priority patent/EP1687017B1/fr
Publication of WO2005056752A2 publication Critical patent/WO2005056752A2/fr
Publication of WO2005056752A3 publication Critical patent/WO2005056752A3/fr
Priority to HK07101416.7A priority patent/HK1095738A1/xx
Publication of WO2005056752A9 publication Critical patent/WO2005056752A9/fr
Priority to AU2010206037A priority patent/AU2010206037A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Definitions

  • bacterial colicins, human porins, and protein transduction domains from diverse species share the motif of a positively charged alpha-helix, frequently with an amphipathic structure, which is capable of inserting into lipid membranes, and delivering larger cargoes intracellularly.
  • PTD's protein transduction domains
  • Recent research reports confirm the successful use of PTD's fused to proteins for their delivery across biological boundaries, including the blood-brain barrier, and the placenta.
  • Another issue of great importance in the delivery of macromolecules in organisms is the need to protect them from proteolytic, nucleolytic and immune degradation and removal while traversing extracellular spaces.
  • An often used approach is coating DNA with proteins capable of surviving the harsh journey to the target.
  • Viral capsid proteins have been quite successful, yet for the purpose of DNA delivery in humans they suffer from a significant drawback - immunogenicity, the capacity to evoke a strong immune reaction greatly reducing the effectiveness of gene therapy.
  • SUMMARY Non-viral polynucleotide delivery vehicles and methods of their use are provided.
  • the disclosure provides modified polynucleotide-binding proteins comprising a protein transduction domain operably linked to a targeting signal, for example a non-nuclear organelle targeting signal.
  • polypeptide comprising at least one HMG box domain, more typically at least two HMG box domains and at least one protein transduction domain.
  • the polypeptide can associate with a polynucleotide causing the polynucleotide to condense.
  • the polypeptide can also coat the polynucleotide. Coating and/or condensing the polynucleotide helps protect the polynucleotide from degradation.
  • the protein transduction domain helps the polypeptide-polynucleotide complex cross membranes and enter the interior of cell or an organelle.
  • the targeting signal helps direct the complex to a site of interest and thereby deliver the polynucleotide.
  • compositions can be used to deliver polynucleotides to specific locations within a cell, including but not limited to mitochondria and chloroplasts.
  • the polynucleotides encode a therapeutic protein or a protein that compensates for non-functional proteins or the absence of proteins. Accordingly, some aspects provide methods for treating diseases, for example diseases related to mitochondria or chloroplasts.
  • BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 Is an diagram of one exemplary plasmid design (left) and exemplary protein structure (right) for TFAM with a PTD domain followed by a MLS.
  • Figures 3A-C are fluorescence micrographs showing MtRed and BrdU (FITC) staining of rhoO (A), normal SY5Y (B) and rhoO cells 16 hrs after transfection with mtDNA complexed with PTD-MLS-TFAM (C).
  • FITC MtRed and BrdU
  • Figure 4 is an agarose gel of PCR products amplifying region around LHON 11778A mutation after SfaNI .
  • Figure 5A is fluorescence micrographs showing normal SY5Y cell 24 hours after transfection with mtDNA-MtEGFP cloned as a fusion gene with ND6 into the BamHI site of mtDNA and costained with MiitoTracker Red.
  • Figure 5B is an immunoblot for EGFP using JL-8 (Clontech) antibody showing a 45 kDa protein fusion product between ND6 and EGFP (top arrow) as well as the 33 kDa EGFP (bottom arrow).
  • Figure 6 is an immunoblot of mtEGFP upon knockdown with siRNA to PolG over five days. Final lane shows failure of EGFP siRNA to achieve knockdown in a similar time frame.
  • Figure 7A is an exemplary schematic of mtEGFP containing a nuclear localization signal (NLS) and PTD cloned into mtDNA containing novel restriction sites, Bglll and Notl.
  • NLS nuclear localization signal
  • Figures 7B-C are fluorescence micrographs showing Sy5y cells expressing NLS-mtEGFP-PTD which localizes to mitochondria and the nucleus.
  • Figure 8A is an exemplary schematic of BamHI site abolished in mtDNA and BamHI cDNA cloned into mtDNA.
  • Figure 8B is a gel 24 hours after transfection showing PCR fragment of mtDNA from cells was digested with BamHI. Lane 1 failed to be digested and lane 2 control mtDNA was digested.
  • Figure 8C is a gel showing mitochondrial lysates from cells that were incubated with DNA containing a BamHI site. Control cells (lane 1) do not show BamHI activity whereas (lane 2) transfected cells possess BamHI activity.
  • Figure 9 is a gel showing recombinant PTD-Bglll targeted to mitochondria caused the rapid removal of mtEGFP protein in cells expressing from a Bglll ⁇ restriction site carrying mtDNA-mtEGFP over a 5 day time period.
  • polypeptides includes proteins and fragments thereof. Polypeptides are disclosed herein as amino acid residue sequences. Those sequences are written left to right in the direction from the amino to the carboxy terminus.
  • amino acid residue sequences are denominated by either a three letter or a single letter code as indicated as follows: Alanine (Ala, A), Arginine (Arg, R), Asparagine (Asn, N), Aspartic Acid (Asp, D), Cysteine (Cys, C), Glutamine (Gin, Q), Glutamic Acid (Glu, E), Glycine (Gly, G), Histidine (His, H), Isoleucine (lie, I), Leucine (Leu, L), Lysine (Lys, K), Methionine (Met, M), Phenylalanine (Phe, F), Proline (Pro, P), Serine (Ser, S), Threonine (Thr, T), Tryptophan (Trp, W), Tyrosine (Tyr, Y), and Valine (Val, V).
  • Variant refers to a polypeptide or polynucleotide that differs from a reference polypeptide or polynucleotide, but retains essential properties.
  • a typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical.
  • a variant and reference polypeptide may differ in amino acid sequence by one or more modifications (e.g., substitutions, additions, and/or deletions).
  • a substituted or inserted amino acid residue may or may not be one encoded by the genetic code.
  • a variant of a polypeptide may be naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Modifications and changes can be made in the structure of the polypeptides of in disclosure and still obtain a molecule having similar characteristics as the polypeptide (e.g., a conservative amino acid substitution). For example, certain amino acids can be substituted for other amino acids in a sequence without appreciable loss of activity. Because it is the interactive capacity and nature of a polypeptide that defines that polypeptide's biological functional activity, certain amino acid sequence substitutions can be made in a polypeptide sequence and nevertheless obtain a polypeptide with like properties. In making such changes, the hydropathic index of amino acids can be considered.
  • hydropathic amino acid index in conferring interactive biologic function on a polypeptide is generally understood in the art. It is known that certain amino acids can be substituted for other amino acids having a similar hydropathic index or score and still result in a polypeptide with similar biological activity. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics.
  • Those indices are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cysteine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (- 3.5); lysine (-3.9); and arginine (-4.5).
  • the relative hydropathic character of the amino acid determines the secondary structure of the resultant polypeptide, which in turn defines the interaction of the polypeptide with other molecules, such as enzymes, substrates, receptors, antibodies, antigens, and the like. It is known in the art that an amino acid can be substituted by another amino acid having a similar hydropathic index and still obtain a functionally equivalent polypeptide. In such changes, the substitution of amino acids whose hydropathic indices are within ⁇ 2 is preferred, those within + 1 are particularly preferred, and those within ⁇ 0.5 are even more particularly preferred.
  • hydrophilicity can also be made on the basis of hydrophilicity, particularly, where the biological functional equivalent polypeptide or peptide thereby created is intended for use in immunological embodiments.
  • the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 ⁇ 1 ); glutamate (+3.0 ⁇ 1); serine (+0.3); asparagine (+0.2); glutamnine (+0.2); glycine (0); proline (-0.5 ⁇ 1 ); threonine (-0.4); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).
  • amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent polypeptide.
  • substitution of amino acids whose hydrophilicity values are within ⁇ 2 is preferred, those within ⁇ 1 are particularly preferred, and those within ⁇ 0.5 are even more particularly preferred.
  • amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like.
  • substitutions that take various of the foregoing characteristics into consideration are well known to those of skill in the art and include (original residue: exemplary substitution): (Ala: Gly, Ser), (Arg: Lys), (Asn: Gin, His), (Asp: Glu, Cys, Ser), (Gin: Asn), (Glu: Asp), (Gly: Ala), (His: Asn, Gin), (lie: Leu, Val), (Leu: lie, Val), (Lys: Arg), (Met: Leu, Tyr), (Ser: Thr), (Thr: Ser), (Tip: Tyr), (Tyr: Trp, Phe), and (Val: lie, Leu).
  • Embodiments of this disclosure thus contemplate functional or biological equivalents of a polypeptide as set forth above.
  • embodiments of the polypeptides can include variants having about 50%, 60%, 70%, 80%, 90%, and 95% sequence identity to the polypeptide of interest.
  • Identity is a relationship between two or more polypeptide sequences, as determined by comparing the sequences.
  • identity also means the degree of sequence relatedness between polypeptide as determined by the match between strings of such sequences.
  • Identity and “similarity” can be readily calculated by known methods, including, but not limited to, those described in (Computational Molecular Biology, Lesk, A.
  • Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. The percent identity between two sequences can be determined by using analysis software (i.e., Sequence Analysis Software Package of the Genetics Computer Group, Madison Wis.) that incorporates the Needelman and Wunsch, (J. Mol. Biol., 48: 443-453, 1970) algorithm (e.g., NBLAST, and XBLAST). The default parameters are used to determine the identity for the polypeptides of the present disclosure.
  • a polypeptide sequence may be identical to the reference sequence, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%.
  • Such alterations are selected from: at least one amino acid deletion, substitution, including conservative and non- conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence.
  • the number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in the reference polypeptide by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in the reference polypeptide.
  • low stringency refers to conditions that permit a polynucleotide or polypeptide to bind to another substance with little or no sequence specificity.
  • purified and like terms relate to the isolation of a molecule or compound in a form that is substantially free (at least 60% free, preferably 75% free, and most preferably 90% free) from other components normally associated with the molecule or compound in a native environment.
  • the term "pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.
  • the term “treating” includes alleviating the symptoms associated with a specific disorder or condition and/or preventing or eliminating said symptoms.
  • "Operably linked” refers to a juxtaposition wherein the components are configured so as to perform their usual function. For example, control sequences or promoters operably linked to a coding sequence are capable of effecting the expression of the coding sequence, and an organelle localization sequence operably linked to protein will direct the linked protein to be localized at the specific organelle.
  • “Localization Signal or Sequence or Domain” or “Targeting Signal or Sequence or Domain” are used interchangeably and refer to a signal that directs a molecule to a specific cell, tissue, organelle, or intracellular region.
  • the signal can be polynucleotide, polypeptide, or carbohydrate moiety or can be an organic or inorganic compound sufficient to direct an attached molecule to a desired location.
  • Exemplary organelle localization signals include nuclear localization signals known in the art and other organelle localization signals known in the art such as those provided in Tables 1 and 2 and described in Emanuelson et al., Predicting Subcellular Localization of Proteins Based on Their N-terminal Amino Acid Sequence. Journal of Molecular Biology.
  • Organelle localization signals of the present disclosure can have 80 to 100% homology to the sequences in Tables 1 and 2.
  • suitable organelle localization signals include those that do not interact with the targeted organelle in a recepto ⁇ ligand mechanism.
  • organelle localization signals include signals having or conferring a net charge, for example a positive charge.
  • Positively charged signals can be used to target negatively charged organelles such as the mitochondria.
  • Negatively charged signals can be used to target positively charged organelles.
  • Protein Transduction Domain or PTD refers to a polypeptide, polynucleotide, carbohydrate, or organic or inorganic compounds that facilitates traversing a lipid bilayer, micelle, cell membrane, organelle membrane, or vesicle membrane.
  • a PTD attached to another molecule facilitates the molecule traversing membranes, for example going from extracellular space to intracellular space, or cytosol to within an organelle.
  • Exemplary PTDs include but are not limited to HIV TAT YGRKKRRQRRR (SEQ. ID NO. 1 ) or RKKRRQRRR (SEQ. ID NO. 2); 11 Arginine residues, or positively charged polypeptides or polynucleotides having 8-15 residues, preferably 9-11 residues.
  • exogenous DNA or "exogenous nucleic acid sequence” or “exogenous polynucleotide” refers to a nucleic acid sequence that was introduced into a cell or organelle from an external source. Typically the introduced exogenous sequence is a recombinant sequence.
  • the term "transfection” refers to the introduction of a nucleic acid sequence into the interior of a membrane enclosed space of a living cell, including introduction of the nucleic acid sequence into the cytosol of a cell as well as the interior space of a mitochondria, nucleus or chloroplast.
  • the nucleic acid may be in the form of naked DNA or RNA, associated with various proteins or the nucleic acid may be incorporated into a vector.
  • vector is used in reference to a vehicle used to introduce a nucleic acid sequence into a cell.
  • a viral vector is virus that has been modified to allow recombinant DNA sequences to be introduced into host cells or cell organelles.
  • organelle refers to cellular membrane bound structures such as the chloroplast, mitochondrion, and nucleus.
  • organelle includes natural and synthetic organelles.
  • non-nuclear organelle refers to any cellular membrane bound structure present in a cell, except the nucleus.
  • polynucleotide generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
  • polynucleotides as used herein refers to, among others, single-and double-stranded DNA, DNA that is a mixture of single-and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double- stranded or a mixture of single- and double-stranded regions.
  • the term "nucleic acid” or “nucleic acid sequence” also encompasses a polynucleotide as defined above.
  • polynucleotide as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
  • the strands in such regions may be from the same molecule or from different molecules.
  • the regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules.
  • One of the molecules of a triple-helical region often is an oligonucleotide.
  • polynucleotide includes DNAs or RNAs as described above that contain one or more modified bases.
  • DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein.
  • DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art.
  • polynucleotide as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, inter alia.
  • "Oligonucleotide(s)" refers to relatively short polynucleotides.
  • RNA:DNA hybrids double-stranded DNAs, among others.
  • compositions and methods for the delivery of a polynucleotide provided herein include polynucleotide-binding polypeptides or polynucleotide- packaging polypeptides having a PTD and optionally a targeting signal or domain.
  • the modified or recombinant polypeptide can be any polypeptide known to bind or package a polynucleotide.
  • the recombinant polypeptide can be used as therapeutic agent either alone or in combination with a polynucleotide.
  • the polynucleotide-binding polypeptide includes at least a portion of a member of the high mobility group (HMG) of proteins, in particular at least one HMG box domain .
  • HMG high mobility group
  • the HMG domain includes a global fold of three helices stabilized in an " L-shaped" configuration by two hydrophobic cores.
  • the high mobility group chromosomal proteins HMG1 or HMG2 which are common to all eukaryotes, bind DNA in a non-sequence-specific fashion, for example to promote chromatin function and gene regulation. They can interact directly with nucleosomes and are believed to be modulators of chromatin structure.
  • HMG proteins include HMG-1/2, HMG-I(Y) and HMG-14/17.
  • the HMG-1/2-box proteins can be further distinguished into three subfamilies according to the number of HMG domains present in the protein, their specific of sequence recognition and their evolutionary relationship.
  • the first group contains chromosomal proteins bound to DNA with no sequence specificity (class I, HMG1 and HMG2), the second ribosomal and mitochondrial transcription factors which show sequence specificity in the presence of another associating factor when bound with DNA (class II, yeast ARS binding protein ABF-2, UBF and mitochondrial transcription factor mtTF-1), and the third gene-specific transcription factors which show sequence specific DNA binding (class III, lymphoid enhancer-binding factors LEF-1 and TCF-1 ; the mammalian sex- determining factor SRY, and the closely related SOX proteins; and the fungal regulatory proteins Mat-MC, Mat-a1 , Ste11 and Rox1).
  • the HMG1/2-box DNA binding domain is about 75 amino acid and contains highly conserved proline, aromatic and basic residues. Common properties of HMG domain proteins include interaction with the minor groove of the DNA helix, binding to irregular DNA structure, and the capacity to modulate DNA structure by bending. SOX (SRY-type HMG box) proteins have critical functions in a number of developmental processes, including sex determination, skeleton formation, pre-B and T cell development and neural induction. SOX9 plays a direct role during chondrogenesis by binding and activating the chondrocyte-spacific enhancer of the Col2a1 gene.
  • the preferred DNA-binding site of SOX9 have been defined to be AGAACAATGG, which contains the SOX core-binding element (SCBE), AACAAT, flanking 5' AG and 3' GG nucleotides enhance binding by SOX9.
  • the recombinant polynucleotide-binding protein has at least one HMG box domain, generally at least two, more particularly 2-5 HMG box domains.
  • the HMG box domain can bind to an AT rich DNA sequence, for example, using a large surface on the concave face of the protein, to bind the minor groove of the DNA. This binding bends the DNA helix axis away from the site of contact.
  • the polynucleotide binding polypeptide can have at least one polynucleotide binding domain, typically two or more polynucleotide binding domains.
  • polynucleotide binding domains known in the art include, but are not limited to helix-turn-helix motifs including homeodomains and POU domains; zinc finger domains such as C 2 H 2 and C 2 C 2 ; amphipathic helix domains such as leucine zipper and helix-loop-helix domains; and histone folds.
  • the polynucleotide binding domain can be specific for a specific polynucleotide sequence, or preferably non-specifically binds to a polynucleotide.
  • the polynucleotide-binding domain can have more than one type of polynucleotide binding domain.
  • Certain embodiments provide modified polynucleotide-binding polypeptides having a helix-turn-helix motif or at least a polynucleotide binding region of a helix-turn-helix protein.
  • Helix-turn-helix proteins have a similar structure to bacterial regulatory proteins such as the I repressor and cro proteins, the lac repressor and so on which bind as dimers and their binding sites are palindromic. They contain 3 a helical regions separated by short turns which is why they are called helix-turn-helix proteins.
  • One protein helix (helix 3) in each subunit of the dimer occupies the major groove of two successive turns of the DNA helix.
  • the disclosed polynucleotide-binding polypeptides can form dimers or other multi-component complexes, and have 1 to 3 helices.
  • the modified polynucleotide-binding polypeptide includes a homeodomain or a portion of a homeodomain protein.
  • Homeodomain proteins bind to a sequence of 180 base pairs initially identified in a group of genes called homeotic genes. Accordingly, the sequence was called the homeobox. The 180 bp corresponds to 60 amino acids in the corresponding protein. This protein domain is called the homeodomain.
  • Homeodomain- containing proteins have since been identified in a wide range of organisms including vertebrates and plants. The homeodomain shows a high degree of sequence conservation.
  • the homeodomain contains 4 ⁇ helical regions. Helices II and III are connected by 3 amino acids comprising a turn. This region has a very similar structure to helices II and III of bacterial DNA binding proteins.
  • Yet another embodiment provides a modified polynucleotide-binding polypeptide having a zinc finger domain or at least a portion of a zinc finger protein. Zinc finger proteins have a domain with the general structure: Phe (sometimes Tyr) - Cys - 2 to 4 amino acids - Cys - 3 amino acids - Phe (sometimes Tyr) - 5 amino acids - Leu - 2 amino acids - His - 3 amino acids - His. The phenylalanine or tyrosine residues which occur at invariant positions are required for DNA binding.
  • the SP1 transcription factor which binds to the GC box found in the promoter proximal region of a number of genes has 3 fingers.
  • This type of zinc finger which has 2 cysteines and 2 histidines is called a C 2 H 2 zinc finger.
  • Another type of zinc finger which binds zinc between 2 pairs of cysteines has been found in a range of DNA binding proteins.
  • the general structure of this type of zinc finger is: Cys - 2 amino acids - Cys - 13 amino acids - Cys - 2 amino acids - Cys. This is called a C 2 C 2 zinc finger.
  • Another embodiment provides a modified polynucleotide-binding polypeptide having a leucine zipper or at least a portion of a leucine zipper protein.
  • the first leucine zipper protein was identified from extracts of liver cells, and it was called C/EBP because it is an enhancer binding protein and it was originally thought to bind to the CAAT promoter proximal sequence.
  • C/EBP will only bind to DNA as a dimer.
  • the region of the protein where the two monomers join to make the dimer is called the dimerization domain. This lies towards the C- terminal end of the protein.
  • leucine residue occurs every seventh amino acid over a stretch of 35 amino acids. If this region were to form an a helix then all of these leucines would align on one face of the helix. Because leucine has a hydrophobic side chain, one face of the helix is very hydrophobic. The opposite face has amino acids with charged side chains which are hydrophilic. The combination of hydrophobic and hydrophilic characteristics gives the molecule is amphipathic moniker. Adjacent to the leucine zipper region is a region of 20-30 amino acids which is rich in the basic (positively charged) amino acids lysine and arginine.
  • C/EBP is thought to bind to DNA by these bZIP regions wrapping round the DNA helix
  • the leucine zipper - bZIP structure has been found in a range of other proteins including the products of thejun and fos oncogenes. Whereas C/EBP binds to DNA as a homodimer of identical subunits, fos cannot form homodimers at all and jun/jun homodimers tend to be unstable. However fos/jun heterodimers are much more stable.
  • AP1 binds to a variety of promoters and enhancers and activates transcription.
  • the consensus AP1 binding site is TGACTCA (SEQ. ID. NO.: 3) which is palindromic.
  • Another embodiment provides a modified polynucleotide-binding polypeptide having helix-loop-helix domain or a polynucleotide binding portion of a helix-loop-helix protein.
  • Helix-loop-helix proteins are similar to leucine zippers in that they form dimers via amphipathic helices. They were first discovered as a class of proteins when a region of similarity was noticed between two enhancer binding proteins called E47 and E12.
  • the modified polynucleotide binding polypeptide includes a histone polypeptide, a fragment of a histone polypeptide, or at least one histone fold. Histone folds exist in histone polypeptides monomers assembled into dimers.
  • Histone polypeptides include H2A, H2B, H3, and H4 which can form heterodimers H2A-2B and H3-H4. It will be appreciated that histone-like polypeptides can also be used in the disclosed compositions and methods. Histone-like polypeptides include, but are not limited to, HMf or the histone from Methanothermous fervidus, other archaeal histones known in the art, and histone-fold containing polypeptides such as MJ1647, CBF, TAFII or transcription factor IID, SPT3, and DM-DRAP (Sanderman, K. et al. (1998) CMLS. Cell. Mol. Life Sci. 54:1350-1364, which is incorporated by reference in its entirety).
  • TFAM modified mitochondrial transcription factor A
  • HMG high mobility group
  • TFAM as well as other HMG proteins bind, wrap, bend, and unwind DNA.
  • embodiments of the present disclosure include polypeptides that induce a structural change in the polynucleotide when the polypeptide binds or becomes associated with the polynucleotide. By inducing a conformational change in the polynucleotide, the polypeptide packages the polynucleotide. It has been reported that TFAM binds to mitochondrial DNA in a ratio of 900:1 (Alam, T. I.
  • polynucleotide-binding polypeptide used in the compositions and methods disclosed herein can vary depending on the size and amount of the polynucleotide to be delivered. Suitable ratios of polynucleotide-binding polypeptide to base pairs of polynucleotide to be delivered include, but are not limited to, about 1 :1 to 1 :1 ,000; more preferably 1 :100; even more preferably 1 : about 10 to about 20 base pairs of polynucleotide to be delivered.
  • TFAM another polynucleotide-binding polypeptide, or a combination of two or more polynucleotide-binding polypeptides can be added to a polynucleotide to wrap or cover the polynucleotide, and thereby package the polynucleotide and protected it from degradation.
  • TFAM can be modified to include a PTD and optionally a targeting signal.
  • the targeting signal can include a sequence of monomers that facilitates the localization of the molecule to a specific tissue, cell, or organelle.
  • the monomers can be amino acids, nucleotide or nucleoside bases, or sugar groups such as glucose, galactose, and the like which form carbohydrate targeting signals.
  • the polynucleotide-binding polypeptide can be modified to include a protein transduction domain (PTD), also known as cell penetrating peptides (CPPS).
  • PTDs are known in the art, and include but are not limited to small regions of proteins that are able to cross a cell membrane in a receptor- independent mechanism (Kabouridis, P. (2003) Trends in Biotechnology (11):498-503). Although several of PTDs have been documented, the two most commonly employed PTDs are derived from TAT (Frankel and Pabo, 1988) protein of HIV and Antennapedia transcription factor from Drosophila, whose PTD is known as Penetratin (Derossi et al., (1994) J Biol Chem.
  • the Antennapedia homeodomain is 68 amino acid residues long and contains four alpha helices (SEQ. ID NO. 4).
  • Penetratin is an active domain of this protein which consists of a 16 amino acid sequence derived from the third helix of Antennapedia.
  • TAT protein (SEQ. ID NO. 5) consists of 86 amino acids and is involved in the replication of HIV-1.
  • the TAT PTD consists of an 11 amino acid sequence domain (residues 47 to 57; YGRKKRRQRRR (SEQ. ID. NO. 1 )) of the parent protein that appears to be critical for uptake (Vives et al., 1997).
  • TAT has been favored for fusion to proteins of interest for cellular import.
  • Q- A substitutions of Glutatmine to Alanine, i.e., Q- A, have demonstrated an increase in cellular uptake anywhere from 90% (Wender et al. 2000) to up to 33 fold in mammalian cells.
  • PTDs that are cationic or amphipathic.
  • exemplary PTDs include but are not limited to poly-Arg - RRRRRRR (SEQ. ID. NO.: 6); PTD-5 - RRQRRTSKLMKR (SEQ. ID. NO.: 7); Transportan GWTLNSAGYLLGKINLKALAALAKKIL (SEQ. ID. NO.: 8); KALA - WEAKLAKALAKALAKHLAKALAKALKCEA (SEQ. ID.
  • the modified polynucleotide-binding polypeptide is optionally modified to include a targeting signal or domain.
  • the targeting signal or sequence can be specific for a tissue, organ, cell, organelle, non-nuclear organelle, or cellular compartment.
  • the compositions disclosed herein can be modified with galactosyl-terminating macromolecules to target the compositions to the liver or to liver cells. The modified compositions selectively enter hepatocytes after interaction of the carrier galactose residues with the asialoglycoprotein receptor present in large amounts and high affinity only on these cells.
  • compositions disclosed here can be targeted to specific intracellular regions, compartments, or organelles. Additional embodiments of the present disclosure are directed to specifically delivering polynucleotides to intracellular compartments or organelles.
  • the polynucleotides can encode a polypeptide or interfere with the expression of a different polynucleotide.
  • Eukaryotic cells contain membrane bound structures or organelles. Organelles can have single or multiple membranes and exist in both plant and animal cells. Depending on the function of the organelle, the organelle can consist of specific components such as proteins and cofactors.
  • the polynucleotides delivered to the organelle can encode polypeptides that can enhance or contribute to the functioning of the organelle.
  • nucleic acids are replicated, transcribed, and translated within these organelles. Proteins are imported and metabolites are exported. Thus, there is an exchange of material across the membranes of organelles.
  • polynucleotides encoding mitochondrial polypeptides are specifically delivered to mitochondria.
  • organelles include the nucleus, mitochondrion, chloroplast, lysosome, peroxisome, Golgi, endoplasmic reticulum, and nucleolus.
  • Synthetic organelles can be formed from lipids and can contain specific proteins within the lipid membranes. Additionally, the content of synthetic organelles can be manipulated to contain components for the translation of nucleic acids.
  • Compositions disclosed herein can include one or more nuclear localization signals.
  • Nuclear localization signals or domains are known in the art and include for example, SV 40 T antigen or a fragment thereof, such as PKKKRKV (SEQ. ID. NO.: 10).
  • the NLS can be simple cationic sequences of about 4 to about 8 amino acids, or can be bipartite having two interdependent positively charged clusters separated by a mutation resistant linker region of about 10-12 amino acids. Additional representative NLS include but are not limited to GKKRSKV (SEQ. ID. NO.: 11 ); KSRKRKL (SEQ. ID. NO.: 12);
  • modified polynucleotide- binding polypeptides are disclosed that specifically deliver polynucleotides to mitochondria.
  • Mitochondria contain the molecular machinery for the conversion of energy from the breakdown of glucose into adenosine triphosphate (ATP). The energy stored in the high energy phosphate bonds of ATP is then available to power cellular functions. Mitochondria are mostly protein, but some lipid, DNA and RNA are present. These generally spherical organelles have an outer membrane surrounding an inner membrane that folds (cristae) into a scaffolding for oxidative phosphorylation and electron transport enzymes. Most mitochondria have flat shelf-like cristae, but those in steroid secreting cells may have tubular cristae. The mitochondrial matrix contains the enzymes of the citric acid cycle, fatty acid oxidation and mitochondrial nucleic acids.
  • Mitochondrial DNA is double stranded and circular.
  • Mitochondrial RNA comes in the three standard varieties; ribosomal, messenger and transfer, but each is specific to the mitochondria. Some protein synthesis occurs in the mitochondria on mitochondrial ribosomes that are different than cytoplasmic ribosomes. Other mitochondrial proteins are made on cytoplasmic ribosomes with a signal peptide that directs them to the mitochondria.
  • the metabolic activity of the cell is related to the number of cristae and the number of mitochondria within a cell. Cells with high metabolic activity, such as heart muscle, have many well developed mitochondria. New mitochondria are formed from preexisting mitochondria when they grow and divide.
  • the inner membranes of mitochondria contain a family of proteins of related sequence and structure that transport various metabolites across the membrane. Their amino acid sequences have a tripartite structure, made up of three related sequences about 100 amino acids in length. The repeats of one carrier are related to those present in the others and several characteristic sequence features are conserved throughout the family.
  • Targeting to specific polynucleotides to organelles can be accomplished by modifying the disclosed compositions to express specific organelle targeting signals. These sequences target specific organelles, but in some embodiments the interaction of the targeting signal with the organelle does not occur through a traditional recepto igand interaction.
  • the eukaryotic cell comprises a number of discrete membrane bound compartments, or organelles.
  • each organelle is largely determined by its unique complement of constituent polypeptides. However, the vast majority of these polypeptides begin their synthesis in the cytoplasm. Thus organelle biogenesis and upkeep require that newly synthesized proteins can be accurately targeted to their appropriate compartment. This is often accomplished by amino-terminal signaling sequences, as well as post-translational modifications and secondary structure. For mitochondria, several amino-terminal targeting signals have been deduced and are included, in part, in Table 1.
  • the organelle targeting signal can contain at least two, preferably 5-15, most preferably about 11 charged groups, causing the targeting signal to be drawn to organelles having a net opposite charge.
  • the targeting signal can contain a series of charged groups that cause the targeting signal to be transported into an organelle either against or down an electromagnetic potential gradient.
  • Suitable charged groups are groups that are charged under intracellular conditions such as amino acids with charged functional groups, amino groups, nucleic acids, and the like.
  • Mitochondrial localization/targeting signals generally consist of a leader sequence of highly positively charged amino acids. This allows the protein to be targeted to the highly negatively charged mitochondria.
  • the mitochondrial localization signal of some embodiments is drawn to mitochondria because of charge.
  • a protein In order to enter the mitochondria, a protein generally must interact with the mitochondrial import machinery, consisting of the Tim and Tom complexes (Translocase of the Inner/Outer Mitochondrial Membrane). With regard to the mitochondrial targeting signal, the positive charge draws the linked protein to the complexes and continues to draw the protein into the mitochondria. The Tim and Tom complexes allow the proteins to cross the membranes. Accordingly, one embodiment of the present disclosure delivers compositions of the present disclosure to the inner mitochondrial space utilizing a positively charged targeting signal and the mitochondrial import machinery. In another embodiment, PTD- linked polypeptides containing a mitochondrial localization signal do not seem to utilize the TOM/TIM complex for entry into the mitochondrial matrix, see Del Gaizo et al. (2003) Mol Genet Metab.
  • modified compositions disclosed herein specifically deliver polynucleotides to chloroplasts by including a chloroplast localization signal or domain.
  • chloroplasts several amino-terminal targeting signals have been deduced and are included, in part, in Table 2.
  • the chloroplast is a photosynthetic organelle in eukaryotes with a double surrounding membrane.
  • the fluid inside the double-membrane is called the stroma.
  • the chloroplast has a nucleoid region to house its circular, naked DNA.
  • the stroma is also the site of the Calvin Cycle.
  • the Calvin Cycle is the series of enzyme-catalyzed chemical reactions that produce carbohydrates and other compounds from carbon dioxide.
  • thylakoids Within the stroma are tiny membrane sacs called thylakoids.
  • the sacs are stacked in groups. Each group is called a granum. There are many grana in each chloroplast.
  • the thylakoid membranes are the site of photosynthetic light reactions.
  • the thylakoids have intrinsic and extrinsic proteins, some with special prosthetic groups, allowing for electrons to be moved from protein complex to protein complex. These proteins constitute an electron transport system sometimes known as the Z-scheme.
  • the prosthetic group for two critical membrane proteins (P680 and P700) is a chlorophyll a pigment molecule. These chlorophyll-binding proteins give the thylakoids an intense green color.
  • the many thylakoids in a chloroplast give the chloroplast a green color.
  • the many chloroplasts in a leaf mesophyll cell give that cell a green color.
  • the many mesophyll cells in a leaf give the leaf a green color.
  • the chlorophyll molecule absorbs light energy and an electron is boosted within the electron cloud in a resonating chemical structure surrounding a magnesium ion. This excited electron is removed by the surrounding electron transport proteins in the membrane. The movement of these electrons, and accompanying protons, results ultimately in the trapping of energy in a phosphate bond in ATP.
  • the thylakoid is thus the location for light absorption and ATP synthesis.
  • the stroma uses the ATP to store the trapped energy in carbon- carbon bonds of carbohydrates.
  • Modified Polynucleotide-Binding Polypeptide Polynucleotide Complexes
  • Modified polynucleotide-binding polypeptides having a protein transduction domain, and optionally, a targeting signal can be combined with a polynucleotide of interest to form a polypeptide-polynucleotide complex.
  • the modified polypeptide can reversibly bind the polynucleotide of interest.
  • the binding or interaction between the modified polypeptide and the polynucleotide of interest is strong enough to protect the polynucleotide from degradation but reversible so that the polynucleotide maintains its biological activity once it has been delivered to the cell or organelle.
  • the biological activity of the polynucleotide can include expressing the polypeptide encoded by the polynucleotide or the enzymatic activity of the polynucleotide if it is a ribozyme or DNAzyme.
  • Another embodiment provides a method for transfecting a non-nuclear organelle by combining a polynucleotide-binding polypeptide, for example TFAM, with a polynucleotide to be delivered and an amount of a lipid and/or polyamine to form a complex and contacting a cell, for example a mammalian cell, with the complex .
  • the polynucleotide-binding protein optionally includes a PTD and optionally a targeting signal.
  • the lipid and/or polyamine can be branched or unbranched, saturated or unsaturated, and typically has a carbon chain length of about 6 to about 50 carbons, more typically about 10 to about 30 carbons, even more typically about 15 to about 20 carbons.
  • a nuclease can also be delivered to the non-nuclear organelle. The nuclease can be selected so that it cleaves endogenous nucleic acids, but does not cleave the heterologous nucleic acids that are introduced into the non-nuclear organelle.
  • a transfected non-nuclear organelle for example a mitochondrion
  • a transfected non-nuclear organelle can be have a nuclease delivered to it wherein the nuclease is selected so that it cleaves the transfected nucleic acids or the heterologous nucleic acids in the non-nuclear organelle.
  • the polynucleotide of interest is operably linked to a promoter or other regulatory elements known in the art.
  • the polynucleotide can be a vector such as an expression vector.
  • the engineering of polynucleotides for expression in a prokaryotic or eukaryotic system may be performed by techniques generally known to those of skill in recombinant expression.
  • An expression vector typically comprises one of the disclosed compositions under the control of one or more promoters.
  • the "upstream” promoter stimulates transcription of the inserted DNA and promotes expression of the encoded recombinant protein. This is the meaning of "recombinant expression” in the context used here.
  • Expression vectors containing the appropriate nucleic acids and transcriptional/translational control sequences in order to achieve protein or peptide expression in a variety of host- expression systems.
  • Cell types available for expression include, but are not limited to, bacteria, such as £. coli and ⁇ . subtilis transformed with recombinant phage DNA, plasmid DNA or cosmid DNA expression vectors. It will be appreciated that any of these vectors may be packaged and delivered using one or more of the disclosed polynucleotide packaging polypeptides.
  • Expression vectors for use in mammalian cells ordinarily include an origin of replication (as necessary), a promoter located in front of the gene to be expressed, along with any necessary ribosome binding sites, RNA splice sites, polyadenylation site, and transcriptional terminator sequences.
  • the origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV) source, or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.
  • the promoters may be derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Further, it is also possible, and may be desirable, to utilize promoter or control sequences normally associated with the desired gene sequence, provided such control sequences are compatible with the host cell systems.
  • a number of viral based expression systems may be utilized, for example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40 (SV40).
  • the early and late promoters of SV40 virus are useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication. Smaller or larger SV40 fragments may also be used, provided there is included the approximately 250 bp sequence extending from the Hindlll site toward the Bgll site located in the viral origin of replication.
  • the coding sequences may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination.
  • Insertion in a non-essential region of the viral genome will result in a recombinant virus that is viable and capable of expressing proteins in infected hosts.
  • Specific initiation signals may also be required for efficient translation of the disclosed compositions. These signals include the ATG initiation codon and adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may additionally need to be provided.
  • the initiation codon must be in-frame (or in-phase) with the reading frame of the desired coding sequence to ensure translation of the entire insert.
  • exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic.
  • the efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements or transcription terminators.
  • the poly A addition site is placed about 30 to 2000 nucleotides "downstream" of the termination site of the protein at a position prior to transcription termination.
  • stable expression is preferred.
  • cell lines that stably express constructs encoding proteins may be engineered.
  • host cells can be transformed with vectors controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker.
  • appropriate expression control elements e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.
  • engineered cells may be allowed to grow for 1-2 days in an enriched medium, and then are switched to a selective medium.
  • the selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci, which in turn can be cloned and expanded into cell lines.
  • One embodiment provides a modified TFAM polypeptide having at least one PTD, and optionally, at least one targeting signal, for example, a nuclear localization signal or mitochondrial localization signal.
  • the modified TFAM can be associated with a polynucleotide of interest. The association can be accomplished in vitro or in vivo.
  • TFAM can be mixed in amounts sufficient to wrap or bind the polynucleotide of interest. Typically, one molecule of TFAM wraps about 15 base pairs of a target polynucleotide. Enough modified TFAM can be added to a polynucleotide of interest to completely coat the exterior of the polynucleotide and/or to condense the polynucleotide.
  • the polynucleotide is packaged so that the PTD and the optional targeting signal are displayed on the surface of the packaged polynucleotide. It will be appreciated that more than one polynucleotide can be packaged into a single complex using more than one modified polynucleotide-binding or packaging polypeptides.
  • the polynucleotide generally encodes a functional polypeptide, an antisense polynucleotide, or an inhibitory RNA and is packaged with the modified polynucleotide-binding polypeptide. At least one cell is contacted with the resulting complex either in vitro or in vivo.
  • the protein transduction domain facilitates crossing the cell's outer membrane and delivers the polynucleotide to the interior of the cell.
  • an optional targeting signal or domain facilitates the localization of the polynucleotide of interest to the a region of interest, for example to the mitochondrion or nucleus.
  • the polynucleotide of interest can be transcribed and ultimately translated.
  • the polynucleotide of interest is an antisense polynucleotide or enzymatic polynucleotide
  • the polynucleotide of interest can act at or near the deliver site, for example in the cytosol or in an organelle.
  • inhibitory polynucleotides are unstable in vivo, in part, because endogenous enzymes and immune responses actively degrade inhibitory polynucleotides, for example small inhibitory RNA (siRNA).
  • siRNA technology is known in the art, and any siRNA, including single or multi-stranded siRNAs, can be used with the present disclosure.
  • siRNA can be combined with a polynucleotide-binding polypeptide having a protein transduction domain, and optionally, a targeting signal to form a complex.
  • the modified polynucleotide-binding polypeptide can associate with the siRNA so that the siRNA is wrapped, covered, condensed, or bound by the modified polypeptide thereby protecting the siRNA from enzymatic degradation.
  • the association is reversible such that upon delivery of the siRNA to the desired destination, the siRNA can function to inhibit the transcription or translation of its target polynucleotide.
  • Another exemplary embodiment provides a method for transfecting a host, a host's cell, or a host's cellular organelle, for example the nucleus, mitochondria, or chloroplasts, including the steps of contacting a host's cell with a complex including a modified polynucleotide-binding polypeptide having at least one PTD, and optionally, at least one targeting signal, in combination with a polynucleotide of interest.
  • the polynucleotide-polypeptide complex acts as a non-viral vector.
  • Cells from one host can be transfected and administered to a second host, or a host's cells can be transfected and administered to the host. The transfection can occur in vivo or in vitro.
  • Suitable cells for transfection include cells capable of being transfected, for example eukaryotic or prokaryotic cells.
  • the cells can be somatic, quiescent, embryonic, mitotic, stem cells, progenitor cells, germ line cells, pluripotent cells, totipotent cells, embryonic stem cells, heterologous cells, undifferentiated, partially differentiated, endoderm, mesoderm, ectoderm, immortalized, or primary cultures.
  • Organelle targeting signals of the present disclosure include polypeptides having a net positive charge, an NLS, and those listed in Tables 1 and 2.
  • Suitable PTDs include but are not limited to HIV TAT YGRKKRRQRRR (SEQ. ID NO. 1 ) or RKKRRQRRR (SEQ. ID NO.
  • compositions include a targeting signal, for example an organelle targeting signal, which causes the complex to associate with the organelle, typically to an organelle having a net negative charge or a region having a negative charge.
  • a targeting signal for example an organelle targeting signal, which causes the complex to associate with the organelle, typically to an organelle having a net negative charge or a region having a negative charge.
  • the association of the targeting signal with the organelle does not occur through a recepto igand interaction.
  • the association of the organelle and complex can be ionic, non-covalent, covalent, reversible or irreversible.
  • Exemplary complex:organelle associations include but are not limited to protein-protein, protein-carbohydrate, protein-nucleic acid, nucleic acid-nucleic acid, protein-lipid, lipid-carbohydrate, antibody-antigen, or avidin-biotin.
  • the organelle targeting signal of the complex can be a protein, peptide, antibody, antibody fragment, lipid, carbohydrate, biotin, avidin, steptavidin, chemical group, or other ligand that causes specific association between the organelle and complex, preferably an electromagnetic association as between oppositely charged moieties.
  • the specific interaction between the introduced complex and its target for example a specific type of cell or an organelle, can be accomplished by at least two methods.
  • a recombinant non-viral complex can include a recombinant polypeptide that expresses a targeting signal that interacts with the targeted the organelle.
  • the complex expresses a outer polypeptide that is specific to the target organelle.
  • the complex is modified to incorporate an exogenous targeting protein to which an organelle binds.
  • a complex can include a modified recombinant polypeptide that specifically interacts with a desired cell, tissue, organ, or organelle, for example by expressing a amino acid sequence that interacts with the specific cell or organelle. It will be appreciated by those of skill in the art that the complex can be chemically modified to have a net positive or negative charge depending on the modification agent.
  • the complex can be coated with polylysine or other agents containing a primary amino group.
  • amino groups can be linked to the complex or compound containing amino groups can be linked to the complex.
  • the linkage can be reversible or irreversible, covalent or non-covalent.
  • Other charged groups for conferring a charge to a compound are known in the art and can be incorporated into the complex.
  • Nucleic acids including but not limited to polynucleotides, anti-sense nucleic acids, peptide nucleic acids, natural or synthetic nucleic acids, nucleic acids with chemically modified bases, RNA, DNA, RNA-DNA hybrids, enzymatic nucleic acids such as ribozymes and DNAzymes, native/endogenous genes and non-native/exogenous genes and fragments or combinations thereof, can be introduced into a cell or organelle of a host cell, in particular cells or organelles that can transcribe and or translate nucleic acids into proteins such as the nucleus, mitochondria and chloroplasts. In one embodiment of the present disclosure, all or part of the mitochondrial or chloroplastic genome can be introduced into an organelle.
  • the nucleic acids can be introduced into the organelle with the complex when the complex crosses the organelle membrane via protein transduction domains.
  • Another embodiment provides a method for transfecting cellular organelles, for example eukaryotic organelles, by contacting the cell with a complex including a polynucleotide-binding polypeptide in combination with a polynucleotide, wherein the polynucleotide-binding polypeptide includes a PTD and optionally, a targeting signal or domain.
  • the targeting signal can be a polypeptide, modified or unmodified, displayed on the surface of the complex which enables the complex to specifically associate with the target cell or organelle.
  • Exemplary targeting signals include, nuclear localization signals, mitochondrial targeting signals including the targeting signals listed in TABLE 1 and other signals having a net positive charge.
  • the complex can further associates with its specific target organelle or intracellular region of the cell and the polynucleotide can be introduced into the organelle.
  • Introduction of the polynucleotide into the organelle can be accomplished by transducing the polynucleotide across organelle membranes via a protein transduction domain expressed on a surface of the complex.
  • a polynucleotide into the cytosol of a eukaryotic cell in an intact functional form, can be accomplished using standard techniques known to those skilled in the art or through modification of the recombinant polynucleotide- binding polypeptide with a protein transduction domains.
  • transfection procedures include but are not limited to microinjection, electroporation, calcium chloride premeablization, polyethylene glycol permeabilization, protoplast fusion or cationic lipid premeablization.
  • a polynucleotide-binding polypeptide is modified to include a Protein Transduction Domain that enables the polypeptide bound to a polynucleotide to be transduced across a lipid bilayer including a cellular membrane, organelle membrane, or plasma membrane.
  • Suitable PTDs include but are not limited to an 11 Arginine PTD or Tat-PTD (SEQ. ID NOs. 3 or 4) and poly-Arg - RRRRRRR (SEQ. ID. NO.: 6); PTD-5 - RRQRRTSKLMKR (SEQ. ID. NO.: 7); Transportan GWTLNSAGYLLGKINLKALAALAKKIL (SEQ. ID.
  • a method for introducing exogenous nucleic acid sequences into a mitochondrion of a mammalian cell. Any mitochondrial transfection technique should ensure that a nucleic acid crosses three membranes (the plasma membrane and the outer and inner mitochondrial membranes), addresses the high copy of mtDNA molecules, and utilizes a minimal, circular mitochondrial replicon.
  • a recombinant polynucleotide-binding polypeptide is used as a delivery vehicle for introducing nucleic acid sequences into an organelle, for example the mitochondrion.
  • the recombinant polypeptide packages the polynucleotides to prevent them from being degraded, and to condense the polynucleotides for delivery. Condensation of polynucleotides includes the ordered structure of polynucleotides under concentrated conditions.
  • a recombinant polynucleotide- binding polypeptide having a PTD and a mitochondrial targeting signal is used for mitochondrial transfection. This approach allows for direct manipulation of mtDNA and introduction of the circular genome at high-copy number. In one embodiment this method is used to manipulate or replace mtDNA. In another embodiment the entire human mitochondrial genome (SEQ ID NO. 218) can be replaced by introduced sequences.
  • Rho° cells can be first generated to remove endogenous mtDNA, followed by mitochondrial transfection, resulting in the entire mitochondrial genome of cells being replaced.
  • mitochondria can be transfected without first proceeding with the generation of Rho° cells.
  • the introduced nucleic acid will be incorporated (recombined) with the existing endogenous mtDNA sequences resulting in the manipulation of the mtDNA sequences. Either method can be used to restore full functionality to damaged mitochondria.
  • Another embodiment provides a method for modifying the genome of a non-nuclear organelle, for example a mitochondrion, comprising transfecting the non-nuclear organelle with a polynucleotide encoding an enzyme that specifically cleaves the non-nuclear organelle's genome but does not cleave the polynucleotide.
  • An exemplary enzyme includes, but is not limited to, a nuclease such as BamHI . It will be appreciated that any enzyme can be used that selectively cleaves nucleic acids endogenous to the non-nuclear organelle without cleaving heterologous nucleic acids.
  • Heterologous nucleic acids refers to nucleic acids introduced from another organism or from a source other than the mitochondrion or host organism of the mitochondrion.
  • the polynucleotide encoding the enzyme can be delivered alone or in combination with second polynucleotide using the methods described herein.
  • the second polynucleotide can encode a second polypeptide, for example, that functions inside or outside of the non-nuclear organelle.
  • the second polypeptide can function in the nucleus and can be a transcription factor, an enhancer or a suppressor of gene activation of transcription, a subunit of a transcription factor, a DNA binding polypeptide or the like.
  • the second polypeptide can act specifically or non-specifically on one or more specific genes or nucleic acid sequences.
  • the second polypeptide expressed in the non-nuclear organelle can be delivered outside of the non- nuclear organelle.
  • the second polypeptide can comprise at least one PTD and optionally a targeting signal to facilitate translocation of the second polypeptide to a desired intracellular or extracellular location, for example the nucleus, cytoplasm, plasma membrane, etc.
  • the second polypeptide can encode a secreted polypeptide, an intracellular polypeptide, a transmembrane polypeptide, or a polypeptide that is at least partially displayed on the exterior surface of a cell membrane.
  • Secreted polypeptides include, but are not limited to, growth factors, cytokines, chemokines, neurotransmitters, insulin, or combinations thereof.
  • the polynucleotide encoding the enzyme can be packaged by a polynucleotide-binding polypeptide and combined with a lipid and/or polyamine vector for delivery to the non-nuclear organelle.
  • An exemplary lipid and/or polyamine vector includes, but is not limited to, LIPOFECTAMINETM.
  • the lipid and/or polyamine vector can be modified to display a targeting signal on the exterior to assist in the delivery of the polynucleotide to the non-nuclear organelle.
  • the polynucleotide encoding the enzymatic polynucleotide also encodes at least a second polypeptide, for example, a polypeptide that compensates for a mutation in the non-nuclear organelle's genome.
  • the second polypeptide can compensate for a null mutation, deletion, inversion, substitution, or transposition in the non-nuclear organelle's genome.
  • the second polypeptide encodes a functional polypeptide that can be delivered to a location outside of the non-nuclear organelle, for example, the nucleus.
  • Still another embodiment provides a method form modifying a genome of a non-nuclear organelle comprising transfecting the non-nuclear organelle with a polynucleotide encoding an enzyme that specifically cleaves heterologous nucleic acids but does not cleave the polynucleotide encoding the enzyme or the endogenous nucleic acids of the non-nuclear organelle.
  • Still another embodiment provides a method for modifying a genome of a non-nuclear organelle comprising contacting a cell with enzymatic polypeptide comprising a PTD and a targeting signal operably linked to the enzymatic polypeptide.
  • the enzymatic polypeptide can be a nuclease or restriction enzyme specific for a restriction site found in the genome of the non-nuclear organelle.
  • the enzymatic polypeptide can cleave nucleic acids at a site found in heterologous nucleic acids and not in nucleic acids endogenous to the non- nuclear organelle.
  • the enzymatic polypeptide can be delivered alone or in combination with a polynucleotide.
  • Suitable mitochondria localization sequences are known to those skilled in the art (see Table 1 ) and include the mitochondrial localization signal of subunit VIII of human cytochrome oxidase, the yeast cytochrome c oxidase subunit IV presequence and the amino-terminal leader peptide of the rat ornithine- transcarbamylase. In one embodiment the introduced sequences are expressed on the viral capsid head.
  • Organelle localization signals are known to those skilled in the art, and any of those signals can be used to target the complex to the target organelle. Localization sequences suitable for use in the present disclosure are described in Emanuelson et al., Predicting Subcellular Localization of Proteins Based on Their N-terminal Amino Acid Sequence.
  • mitochondria localization signals for targeting linked proteins or nucleic acids to the mitochondria is listed in TABLE 1.
  • chloroplast localization signals for targeting linked proteins or nucleic acids to the chloroplasts is listed in TABLE 2.
  • the mitochondria or chloroplast localization signal is operably linked to a virus surface protein. It will be appreciated that part or all of the sequences listed in Tables 1 and 2 can be used as organelle targeting signals.
  • the identification of the specific sequences necessary for translocation of a linked protein into a chloroplast or mitochondria can be determined using predictive software known to those skilled in the art, including the tools located at http://www.mips.biochem.mpg.de/cgi-bin/proj/medgen/mitofilter.
  • Transfection of Plants Another embodiment provides methods and compositions for the transfection of plants, for example the delivery of a polynucleotide to a chloroplast.
  • Techniques for plant transfection are known in the art.
  • Agrobacterium tumefaciens and Agrobacterium rhizogenes both have the ability to transfer portions of their DNA into the genomes of plants and can be used to transfect plant cells. The mechanism by which they transfer DNA is the same, however the differences in the resulting phenotypes are attributed to the presence of a Ti plasmid in Agrobacterium tumefaciens and the Ri plasmid in Agrobacterium rhizogenes.
  • the Ti plasmid DNA induces host plants to grow tumourous masses whereas the Ri plasmid DNA leads to the abundant proliferation of roots.
  • Agrobacterium tumefacies is capable of infecting almost any plant tissue whereas Agrobacterium rhizogenes can only infect roots.
  • the Ti plasmid of Agrobacterium is a large, circular double stranded DNA molecule (T-DNA) of approximately 200 kb, which exist as an autonomous replicating unit.
  • the plasmids are maintained within the bacteria and only a specific region (T-region) approximately 20 kb can be transferred from the bacteria to the host.
  • the Ti plasmid contains a series of genes that code for its own replication, excision from the plasmid, transfer to the host cell, incorporation into the host genome and the induction of tumor formation
  • Agrobacterium can detect and migrate towards injured plant cells through the detection of chemical signals leaking from the wounded plant. This detection process is referred to as chemotaxis.
  • Agrobacterium can recognize plant compounds such as acetosyrinogone, sinapinic acid, coniferyl alcohol, caffeic acid and methylsyringic acid which induce the bacteria's virulence.
  • Agrobacterium must bind itself to the host cell. This binding is achieved by a group of genes located within the bacterial chromosome.
  • the bacteria can anchor at the site of injury, by the production of cellulose fibrils.
  • the fibrils attach to the cell surface of the plant host and facilitate the clustering of other bacteria on the cell surface. It is believed that this clustering many help the successful transfer of T-DNA.
  • the bacterium is free to begin the processing and transfer of the T-region.
  • One embodiment of the present disclosure discloses transfecting a plant cell with Agrobacterium wherein the Agrobacterium has been modified to bind to a plant organgelle, for example a chloroplast.
  • Agrobacterium can be futher modified to encode a nucleic acid of interest for expression in the organelle. Upon binding to the organelle, the Agrobacterium can deliver the target nucleic acid into the chloroplast.
  • the T- region To transfer the T-region of the Ti plasmid to the host cell organelle, the T- region must be processed such that it is excised from the plasmid and directed to the organelle. The T-region is excised from the Ti plasmid and directed into the host cell or organelle. Once properly packaged, the T- complex transfer is mediated by several proteins and is thought to be similar to bacterial conjugation. Once inside the plant cell or organelle, the T-complex is taken through the membrane.
  • the transfection complex comprises a recombinant polypeptide having a protein transduction domain and an organelle localization signal in combination with a polynucleotide.
  • the complex can be introduced into organelles of cells from a cell line.
  • the cell line can be a transformed cell line that can be maintained indefinitely in cell culture, or the cell line can be a primary cell culture.
  • Exemplary cell lines are those available from American Type Culture Collection including plant cell lines which are incorporated herein by reference.
  • the nucleic acid can be replicated and transcribed within the nucleus of a cell of the transfected cell line.
  • the targeting signal can be enzymatically cleaved if necessary such that the complex is free to remain in the target organelle.
  • Any eukaryotic cell can be transfected to produce organelles that express a specific nucleic acid, for example a metabolic gene, including primary cells as well as established cell lines.
  • Suitable types of cells include but are not limited to undifferentiated or partially differentiated cells including stem cells, totipotent cells, pluripotent cells, embryonic stem cells, inner mass cells, adult stem cells, bone marrow cells, cells from umbilical cord blood, and cells derived from ectoderm, mesoderm, or endoderm.
  • Suitable differentiated cells include somatic cells, neuronal cells, skeletal muscle, smooth muscle, pancreatic cells, liver cells, and cardiac cells.
  • Suitable plant cells can be selected from monocots and dicots, and include corn, soybeans, legumes, grasses, and grains such as rice and wheat.
  • the organelle to be targeted is a chloroplast
  • the host cell can be selected from known eukaryotic photosynthetic cells. If the organelle to be transfected is the mitochondrion, than any eukaryotic cell can be used, including mammalian cells, for example human cells.
  • the cells are transfected to either transiently or stably express the exogenous nucleic acid.
  • a DNA construct encoding a reporter gene is integrated into the mitochondrial genome of a cell to produce a stable transgenic cell line that comprises organelles that express the desired reporter gene.
  • siRNA or antisense polynucleotides can be transfected into an organelle using the compositions described herein. 6.
  • Research Tools the present disclosure is used as a tool to investigate cellular consequences of gene expression, for example mtDNA expression, the mechanisms of heteroplasmy, mtDNA replication and inheritance, as well as threshold effects. Mutant mice can be generated using this approach, allowing investigators to study mutations in nuclear and mtDNA not found in nature. More particularly, the methods and compositions disclosed herein can be used to generate cells that contain mitochondria that have identical genotypes or varying degrees of heteroplasmy.
  • Rho 0 cells are first prepared using RNA interference (RNAi).
  • RNAi RNA interference
  • Rho 0 cells can be generated using RNAi to the human mitochondrial DNA polymerase.
  • Exemplary Rho 0 cell lines are generated with RNAi to mitochondrial proteins involved in mtDNA maintenance. These Rho 0 cells are maintained and propagated on pyruvate containing supportive media and then transfected with a functional mitochondria genome. After metabolic selection, by removing pyruvate from supportive media, only those cells that contain successfully transfected mitochondria will survive, thus generating a population of cells that all have identical mitochondria genomes.
  • Cell lines having varying degrees of heteroplasmy can then be generated in a controlled manner by fusing two or more homoplasmy cell lines to generate cybrids.
  • Cybrids can be generated using any of the known technique for introducing organelles into a recipient cell, including but not limited to polyethylene glycol (PEG) mediated cell membrane fusion, cell membrane permeabilization, cell-cytoplast fusion, virus mediated membrane fusion, liposome mediated fusion, microinjection or other methods known in the art. 7.
  • PEG polyethylene glycol
  • the techniques described in the present disclosure can also be used to generated transgenic non-human animals.
  • embryonic stem (ES) cell cybrids have each provided feasible strategies for creating hetero- and homoplasmic mice containing mtDNA from transfected cell lines (i.e. cells that containing transfected mitochondria).
  • an embryonic stem (ES) cell is transfected and injected into the blastocyst of a mammalian embryo as a means of generating chimeric mice.
  • embryonic stem (ES) cell cybrids from transfected cells and ES cell rhos, or from two separately transfected cells are first prepared, followed by blastocyst injection into embryos.
  • transfected non-human organisms and methods making and using them.
  • Single or multicellular non- human organisms preferably non-human mammals, more preferably mice, can be transfected with the compositions described herein by administering the compositions of the present disclosure to the non-human organism.
  • the polynucleotide remains episomal and does not stably integrate into the genome of the host organism.
  • the polynucleotide prevents the expression of a gene of interest.
  • the expression of the polynucleotide in the host can be controlled by the amount of polynucleotide administered to the host.
  • the disclosed transfected non-human organisms have several advantages over traditional transgenic organisms. For example, the transfected organism disclosed herein can be produced in less time that traditional transgenic organisms without sexual reproduction.
  • the expression of the polynucleotide of interest in the host can be directly regulated by the amount of polynucleotide of interest administered to the host. Dosage controlled expression of a polynucleotide of interest can be correlated to observed phenotypes and changes in the transfected animal.
  • kits can be included in the polynucleotide of interest to provide inducible and dosage dependent expression and/or replication. Suitable inducible expression and/or replication control elements are known in the art. 8. Kits The present disclosure is also directed to a kit or pack that supplies the elements necessary to conduct transfection of eukaryotic or prokaryotic organisms, in particular the transfection of organelles.
  • a kit comprising a DNA binding protein construct that includes a protein transduction domain and optionally, a targeting signal and domain. The protein construct can be combined with a polynucleotide to form a complex which can be used to transfect a host or a host cell.
  • the protein construct provided with the kit comprises a nuclear, mitochondrial or chloroplast localization signal selected from those known to target to the organelle, partially listed in Tables I and II.
  • the protein construct comprises a sequence encoding an 11 Arginine residue stretch or HIV- Tat amino acid sequence followed by a mitochondrial localization signal, for example the localization signal of TFAM optionally operably linked to a targeting signal.
  • a kit is provided comprising cells that express the protein construct. The cells can be cultured to produce the protein construct in large quantities which can be harvested, purified, and concentrated.
  • the individual components of the kits can be packaged in a variety of containers, e.g., vials, tubes, microtiter well plates, bottles, and the like.
  • kits can be included in separate containers and provided with the kit; e.g., positive control samples, negative control samples, buffers, cell culture media, etc.
  • the kits will also include instructions for use.
  • the kit includes a construct having a polynucleotide binding domain that hybridizes or binds to a predetermined nucleic acid sequence.
  • kit includes a polynucleotide-binding polypeptide that non-specifically hybridizes or binds to polynucleotides of interest.
  • Suitable genetic based diseases that can be treated with the compositions diclosed herein include but are not limited to: cancer; Canavan disease; Alzheimer's; Parkinson's; hypercholesteremia; cystic fibrosis; anemia; artherosclerosis; muscular dystrophy; AIDS; asthma; diabetes; arthritis; adenosine deaminase deficiency; Gaucher's disease; haemoglobinopathies such as sickle cell anaemia and the thalassemias; and autoimmue diseases.
  • Organelle dysfunction can cause disease in a host, for example a human host or a plant host. In particular, problems with mitochondria or chloroplasts can result in disease.
  • Mitochondrial diseases result from failures of the mitochondria, specialized compartments present in every cell of the body except red blood cells. Cell injury and even cell death are result from mitochondrial failure. If this process is repeated throughout the body, whole systems begin to fail, and the life of the person in whom this is happening is severely compromised.
  • the disease can be in children, for example individuals less that 18 years of age, typically less than 12 years of age, or adults, for example individuals 18 years of age or more.
  • embodiments of the present disclosure are directed to treating a host diagnosed with an organelle related disease, in particular a mitochondrial disease, by introducing a vector into the host cell wherein the vector specifically binds to the organelle and wherein the vector comprises a nucleic acid encoding mitochondrial protein or peptide.
  • the present disclosure encompasses manipulating, augmenting or replacing portions of the mammalian cell mitochondrial genome to treat diseases caused by mitochondrial genetic defects or abnormalities.
  • exemplary mitochondrial diseases include but are not limited to: Alpers Disease; Barth syndrome; ⁇ -oxidation defects; carnitine-acyl-camitine deficiency; carnitine deficiency; co-enzyme Q10 deficiency; Complex I deficiency; Complex II deficiency; Complex III deficiency; Complex IV deficiency; Complex V deficiency; cytochrome c oxidase (COX) deficiency; Chronic Progressive External Ophthalmoplegia Syndrome (CPEO); CPT I Deficiency; CPT II deficiency; Glutaric Aciduria Type II; lactic acidosis; Long-Chain Acyl-CoA Dehydrongenase Deficiency (LCAD); LCHAD; mitochondrial cytopathy; mitochondrial DNA depletion; mitochondrial encephalopathy
  • the respiratory chain consists of four large protein complexes: 1, 11, 111 and IV (cytochrome c oxidase, or COX), ATP synthase, and two small molecules that ferry around electrons, coenzyme Q10 and cytochrome c.
  • the respiratory chain is the final step in the energy-making process in the mitochondrion where most of the ATP is generated.
  • Mitochondrial encephalomyopathies that can be caused by deficiencies in one or more of the specific respiratory chain complexes include MELAS, MERFF, Leigh's syndrome, KSS, Pearson, PEO, NARP, MILS and MNGIE
  • the mitochondrial respiratory chain is made up of proteins that come from both nuclear and mtDNA. Although only 13 of roughly 100 respiratory chain proteins come from the mtDNA, these 13 proteins contribute to every part of the respiratory chain except complex II, and 24 other mitochondrial genes are required just to manufacture those 13 proteins, Thus, a defect in either a nuclear gene or one of the 37 mitochondrial genes can cause the respiratory chain to break down.
  • the scope of the present disclosure includes transfecting mitochondria with at least one or part of one gene involved in mitochondrial function, in particular at least one or part of the 37 mitochondrial genes to restore or increase the function of the respiratory chain.
  • Any or part of a mitochondrial genome for example human mitochondrial genome SEQ ID NO: 218, may be introduced into a host mitochondrion using the methods described herein. Diseases of the mitochondria appear to cause the most damage to cells of the brain, heart, liver, skeletal muscles, kidney and the endocrine and respiratory systems.
  • transfection of mitochondria in these cells and tissues with specific nucleic acids is within the scope of the present disclosure, in particular transfection of mitochondria with nucleic acids encoding mitochondrial-encoded proteins rather than nuclear-encoded proteins.
  • the mitochondria can be transfected to express any protein whether naturally present in the mitochondrion or not or naturally encoded by mtDNA or nuclear DNA.
  • symptoms may include loss of motor control, muscle weakness and pain, gastro-intestinal disorders and swallowing difficulties, poor growth, cardiac disease, liver disease, diabetes, respiratory complications, seizures, visual/hearing problems, lactic acidosis, developmental delays and susceptibility to infection.
  • Exemplary mtDNA mutations that can be addressed by the present disclosure include but are not limited to: tRNA leu - A3243G, A3251G, A3303G, T3250C T3271 C and T3394C; tRNA Lys - A8344G, G11778A, G8363A, T8356C; ND1- G3460A; ND4- A10750G, G14459A; ND6-T14484A; 12S rRNA-A1555G; MTTS2-C12258A; ATPase 6-T8993G, T8993C; tRNA Ser (UCN)-T7511C; 11778 and 14484, LHON mutations as well as mutations or deletions in ND2, ND3, ND5, cytochrome b, cytochrome oxidase Mil, , and ATPase 8.
  • One embodiment of the present disclosure provides a method for restoring or increasing respiratory chain function in host cell including introducing a polynucleotide-binding polypeptide-polynucleotide complex into the host cell, wherein the complex specifically binds to the mitochondrion and comprises a nucleic acid that encodes a respiratory chain protein or peptide.
  • the nucleic acid of the complex can be injected or otherwise delivered into the interior of the mitochondria when the complex targets the mitochondria.
  • Another embodiment of the present disclosure provides a method for restoring or increasing cytochrome oxidase activity in a host including transfecting mitochondria in a cell, for example a skeletal muscle cell, wherein the complex comprises a nucleic acid that encodes cytochrome oxidase or a functional component thereof.
  • a functional component means a part or fragment of the protein or protein complex or subunit that performs a biological function independently or in combination with another protein, fragment, or subunit.
  • Still another embodiment of the present disclosure provides a method of increasing or restoring ⁇ -oxidation in a host including obtaining cells from the host, transfecting an organelle in the cells from the host, introducing a complex comprising a nucleic acid encoding proteins involved in ⁇ -oxidation spiral and carnitine transport, wherein the vector specifically binds to the organelle; and introducing the transfected cells of the host back into the host.
  • Other embodiments of the disclosure are directed to methods of restoring mitochondrial function lost or decreased as a result of point mutations or deletions.
  • KSS, PEO and Pearson are three diseases that result from a type of mtDNA mutation called a deletion (specific portions of the DNA are missing) or mtDNA depletion (a general shortage of mtDNA).
  • cells from hosts diagnosed with KSS, PEO, Pearson or similar disease can have their mitochondria transfected with the recombinant viral vector.
  • a complex comprising a nucleic acid that corresponds to the deletion in the mtDNA causing the diseased state can be introduced into the cells.
  • the complex will bind the organelle and deliver the nucleic acid into the interior of the mitochondria where the nucleic acid is expressed.
  • the expression product can then incorporate into the mitochondria and increase or restore mitochondrial function.
  • the transfected cells can be reintroduced in the host.
  • the host's cells or other cells can be transfected as described herein and introduced into a host having a dysfunctional organelles, in particular mitochondria.
  • the present disclosure encompasses delivering either separately or in combination nucleic acids to the mitochondria that are naturally encoded by mtDNA or nuclear DNA.
  • the present disclosure also contemplates alleviating the symptoms of mitochondrial diseases by creating cells having transfected and non-transfected mitochondria. Alternatively, all of the mitochondria in a cell can be transfected or replaced.
  • One embodiment provides a method for compensating for a mtDNA mutation in a host, the method including identifying a host having a mtDNA mutation, obtaining a cell comprising said mtDNA mutation from said host, transfecting a mitochondrion of the host cell, introducing a complex that specifically binds to the organelle into the host cell, wherein the complex comprises a nucleic acid that encodes a functional product corresponding to the mtDNA mutation, introducing said transfected cell into the host.
  • a nucleic acid that encodes a functional product corresponding to the mtDNA mutation means a sequence that produces a protein without the corresponding mutation.
  • the transfected nucleic acid would encode a wildtype product for the ND4 gene.
  • the non-viral complex can be introduced into the host, for example, intravenously. 10.
  • Administration The compositions provided herein may be administered in a physiologically acceptable carrier to a host. Preferred methods of administration include systemic or direct administration to a cell.
  • the compositions can be administered to a cell or patient, as is generally known in the art for gene therapy applications. In gene therapy applications, the compositions are introduced into cells in order to transfect an organelle.
  • Gene therapy includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or RNA.
  • the modified complex compositions or the recombinant polypeptide alone can be combined in admixture with a pharmaceutically acceptable carrier vehicle.
  • Therapeutic formulations are prepared for storage by mixing the active ingredient having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions.
  • Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronics or PEG.
  • buffers such as phosphate, citrate and other organic acids
  • antioxidants including ascorbic acid
  • compositions of the present disclosure can be administered parenterally.
  • parenteral administration is characterized by administering a pharmaceutical composition through a physical breach of a subject's tissue.
  • Parenteral administration includes administering by injection, through a surgical incision, or through a tissue-penetrating non-surgical wound, and the like.
  • parenteral administration includes subcutaneous, intraperitoneal, intravenous, intraarterial, intramuscular, intrasternal injection, and kidney dialytic infusion techniques.
  • Parenteral formulations can include the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration.
  • Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampules or in multi-dose containers containing a preservative.
  • Parenteral administration formulations include suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, reconsitutable dry (i.e. powder or granular) formulations, and implantable sustained-release or biodegradable formulations. Such formulations may also include one or more additional ingredients including suspending, stabilizing, or dispersing agents.
  • Parenteral formulations may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution. Parenteral formulations may also include dispersing agents, wetting agents, or suspending agents described herein.
  • Sterile injectable formulations may be prepared using non-toxic parenterally-acceptable diluents or solvents, such as water, 1 ,3- butane diol, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic monoglycerides or diglycerides.
  • Other parentally-administrable formulations include microcrystalline forms, liposomal preparations, and biodegradable polymer systems.
  • Compositions for sustained release or implantation may include pharmaceutically acceptable polymeric or hydrophobic materials such as emulsions, ion exchange resins, sparingly soluble polymers, and sparingly soluble salts.
  • Pharmaceutical compositions may be prepared, packaged, or sold in a buccal formulation.
  • Such formulations may be in the form of tablets, powders, aerosols, atomized solutions, suspensions, or lozenges made using known methods, and may contain from about 0.1% to about 20% (w/w) active ingredient with the balance of the formulation containing an orally dissolvable or degradable composition and/or one or more additional ingredients as described herein,.
  • powdered or aerosolized formulations have an average particle or droplet size ranging from about 0.1 nanometers to about 200 nanometers when dispersed.
  • additional ingredients include one or more of the following: excipients, surface active agents, dispersing agents, inert diluents, granulating agents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents, preservatives, physiologically degradable compositions (e.g., gelatin), aqueous vehicles, aqueous solvents, oily vehicles and oily solvents, suspending agents, dispersing agents, wetting agents, emulsifying agents, demulcents, buffers, salts, thickening agents, fillers, emulsifying agents, antioxidants, antibiotics, antifungal agents, stabilizing agents, and pharmaceutically acceptable polymeric or hydrophobic materials.
  • excipients e.g., surface active agents, dispersing agents, inert diluents, granulating agents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents, preservatives, physiologically degradable composition
  • additional ingredients which may be included in the pharmaceutical compositions are known. Suitable additional ingredients are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., Genaro, ed., Easton, Pa. (1985). Dosages and desired concentrations modified vectors disclosed herein in pharmaceutical compositions of the present disclosure may vary depending on the particular use envisioned. The determination of the appropriate dosage or route of administration is well within the skill of an ordinary physician. Animal experiments provide reliable guidance for the determination of effective doses for human therapy. Interspecies scaling of effective doses can be performed following the principles laid down by Mordenti, J. and Chappell, W.
  • Example 1 Recombinant Constructs The 11 amino acid protein transduction domain (PTD) of the HIV Tat protein was cloned upstream and in frame of the mitochondrial localization signal (MLS) of the human mitochondrial transcription factor A (TFAM). For nuclear transfection, the MLS was replaced with the 9 amino acid nuclear localization signal (NLS) of the SV40 virus T Antigen.
  • PTD 11 amino acid protein transduction domain
  • MLS mitochondrial localization signal
  • TFAM human mitochondrial transcription factor A
  • NLS 9 amino acid nuclear localization signal
  • the recombinant protein was expressed in bacteria and isolated on a nickel chelating column utilizing a 6X Histidine tag expressed on the C-terminus immediately downstream of an Enterokinase site.
  • the purified protein was incubated with Enterokinase and further purified on a nickel column where the flow-through was collected. The protein was dialyzed overnight at 4°C against saline containing 33% phospho- buffered saline. Purified protein was concentrated and protein concentration was assessed with the Bradford Assay (Biorad). Purified protein was analyzed with SDS-Page to verify purity. Briefly, full-length human mitochondrial genome was isolated from a mitochondrial preparation from the human neuroblastoma cell line, SH-SY5Y.
  • Example 2 Mitochondrial Expression of GFP GFP (Green Fluorescent Protein) cDNA was mutated at the 270 nucleotide position to generate the following codon change (UGG UGA).
  • UGA is read by the mitochondrial translation machinery as a Tryptophan whereas the nuclear translational machinery reads it as a stop codon-producing a non- fluorescing, curtailed GFP when translated by the nuclear machinery but a full- length fluorescent product when translated in the mitochondria.
  • the resultant mitochondrially encoded GFP cDNA was complexed with the PTD-MLS-Tfam as described above and introduced into SY5Y cell culture prestained with MitoTracker Red. The cells were imaged with confocal 24 hours after transfection.
  • Rho cells generated from wild-type mitochondrial genome containing SY5Ys were transfected with mutant mitochondrial genome from LHON (Leber's Hereditary Optic Neuropathy) cybrids.
  • the LHON mutation is a G->A transition at nucleotide position 11778 of the mitochondrial genome.
  • This mutation removes a SfaNI Restriction site-thus digestion of a 500 bp PCR product generated with primers flanking the restriction site with SfaNI produces in the wild-type condition two smaller products (300 and 200 bp).
  • the PCR product generated from LHON mutant genome cannot be digested and remains as a 500 bp product.
  • the leftmost lane (Lane 1 ) is the PCR product generated from LHON cells and thus fails restriction digestion.
  • Lane 2 is from Rho cells receiving only naked LHON mitochondrial DNA.
  • Lane 3 is from Rho cells receiving only the recombinant PTD-MLS-Tfam.
  • Lane 4 is from Rho cells receiving LHON mtDNA complexed with the recombinant PTD-MLS-Tfam. Lane 5 is control Rho cells alone. Lane 4 shows that the recombinant protein complexed with mutant DNA is capable of introducing a mutant mitochondrial genome into Rho cells.
  • Example 3 Construct Sequence Data TFAM Sequence (Mitochondrial Localization Signal (underlined) (Locus Link ID: 7019) (SEQ. ID.
  • PTD-NLS-TFAM Nuclear Localization Signal (underline) Replaces Mitochondrial; PTD double underline
  • PTD-MLS-TFAM peptide Length 260 (SEQ. ID. NO.: 209)
  • Organism Protein And Percent Identity And Length Of Aligned Region H.sapiens sp:Q00059 - MTT1_HUMAN Transcription 100 % / 246 aa (SEQ. ID. NO.: 211 ): factor 1 , mitochondrial precursor (MTTF1 ) (see ProtEST ) M.musculus ref:NP_033386.1 - transcription factor A, mitochondrial 63 % / 237 aa (SEQ. ID.
  • This vector which combines the three elements of gene delivery described above, allows for the first time the introduction of full-length mitochondrial genomes and exogenous genes cloned into mtDNA into the mitochondrial matrix compartment in both dividing and non-dividing cells.
  • a PTD sequence specifically, a poly-arginine stretch was added to the N-terminal of the vector molecule.
  • the (+) charge of the PTD aids in the apposition to the (-) charged surface of living cells, while its amphipathic nature leads to invading the cellular membrane.
  • FIG. 1 shows that w.t. mtDNA that has been labeled with Alexa 488 dye and complexed with PTD-MLS-TFAM rapidly enters mitochondria of SY5Y cells within 15 minutes.
  • Figure 3 shows the rapid restoration of mtDNA replication and bioenergetic function following introduction of w.t. mtDNA by the disclosed methods.
  • the top image (A) is of rhoO cells stained with MitoTracker Red (MTRed), to localize mitochondria as a function of their ⁇ M, and following incubation for 12 hours with BrdU and immunostained for BrdU with FITC. Low levels of MTRed accumulation were detected, reflecting low ⁇ M, and absence of BrdU staining.
  • Part (B) shows a normal SY5Y cell and part (C) shows a rhoO cell 16 hours after transfection with PTD-MLS-TFAM complexed with w.t. mtDNA. There is a marked increase in MTRed uptake and BrdU staining.
  • Example 6 Functionality of Transfected DNA The functionality of transfected DNA was verified by the rescue of the rhoO phenotype.
  • RhoO cells are cultured cells depleted of endogenous mtDNA by prolonged incubation with ethidium bromide. Such cells survive only in media supplemented with uridine and pyruvate, and do not have measurable activities of the electron transport chain, whose subunits are partially encoded by the mitochondrial genome.
  • MTD-TFAM complexed with LHON mtDNA was added to the media of rhoO cells created from Sy5y cells.
  • Figure 4 shows successful introduction into and replication of LHON mtDNA in rhoO cells.
  • the LHON 11778A mutation causes loss of the SfaNI site present in w.t. mtDNA.
  • a similar w.t.-like pseudogene is amplified and cut by SfaNI .
  • SfaNI w.t.-like pseudogene
  • mainly the introduced LHON mtDNA free of the SfaNI site is found.
  • Example 7 Transfection of EGFP Additional verification of mitochondrial delivery of DNA was achieved by the introduction of the gene for the green fluorescent protein, EGFP.
  • the cDNA for EGFP was engineered such that mitochondria will be able to translate the full-length, fluorescing protein (Codon change at nucleotide position 173 of mtEGFP from UGG UGA), whereas nuclear translation will result in a truncated protein lacking fluorescent activity.
  • the mutagenized, mitochondrial EGFP (mtEGFP) was cloned into the mitochondrial genome at one of two sites (the BamHI site producing ND6 fused to mtEGFP and at the junction of the genes COX3 and ATP6).
  • RNA interference was used to the mtDNA polymerase, polymerase gamma (PolG).
  • mtEGFP was fused with sequences coding for a combination of PTD and the nuclear localization signal (NLS) from Sv40 Large T antigen and cloned into the COX3- ATP6 site.
  • the resulting protein is a fusion of EGFP and NLS+PTD (the Mitochondrial Escape Domain, MED).
  • the MED allows the fusion protein to leave the mitochondria and be targeted to the nucleus.
  • the MED- NLS-EGFP concentrated in the nuclei to a significant extent and was detectable in mitochondria. The process is rather efficient, with more than 10% of cells showing robust nuclear accumulation of mitochondrially-translated protein.
  • Example 9 Digestion of Endogenous DNA Several groups have reported a selective advantage of mutant mtDNA over that of wild-type. To enable the introduced mtDNA to overwhelm any endogenous mtDNA, mutant or otherwise, the BamHI site in ND6 of the cloned mtDNA were abolished. The mutagenesis does not cause an amino acid change. The BamHI restriction endonuclease cDNA was cloned in the COX3- ATP6 site. By abolishing the BamHI site and including the BamHI restriction endonuclease as part of the cloned mtDNA, the BamHI enzyme would restriction digest all endogenous mtDNA and be unable to digest the introduced mtDNA.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)

Abstract

L'invention porte sur des procédés et des compositions permettant de distribuer des polynucléotides. Dans un mode de réalisation, un vecteur non-viral contient une protéine à liaison polynucléotidique recombinante comprenant un domaine de transduction de protéines relié opérationnellement à un signal de ciblage. L'invention concerne aussi des procédés de modification du génome d'organites non-nucléaires.
PCT/US2004/035137 2003-10-24 2004-10-25 Procedes et compositions permettant de distribuer des polynucleotides WO2005056752A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2004297533A AU2004297533B2 (en) 2003-10-24 2004-10-25 Methods and compositions for delivering polynucleotides
ES04817807T ES2411962T3 (es) 2003-10-24 2004-10-25 Métodos y composiciones para suministrar polinucleótidos
JP2006536845A JP4838722B2 (ja) 2003-10-24 2004-10-25 ポリヌクレオチドを送達する方法、及び送達用組成物
CA2543257A CA2543257C (fr) 2003-10-24 2004-10-25 Procedes et compositions permettant de distribuer des polynucleotides
EP04817807A EP1687017B1 (fr) 2003-10-24 2004-10-25 Procédés et compositions permettant de distribuer des polynucleotides
HK07101416.7A HK1095738A1 (en) 2003-10-24 2007-02-07 Methods and compositions for delivering polynucleotides
AU2010206037A AU2010206037A1 (en) 2003-10-24 2010-07-29 Methods and Compositions for Delivering Polynucleotides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51398303P 2003-10-24 2003-10-24
US60/513,983 2003-10-24
US56843604P 2004-05-05 2004-05-05
US60/568,436 2004-05-05

Publications (3)

Publication Number Publication Date
WO2005056752A2 true WO2005056752A2 (fr) 2005-06-23
WO2005056752A3 WO2005056752A3 (fr) 2005-09-29
WO2005056752A9 WO2005056752A9 (fr) 2009-07-23

Family

ID=34681406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/035137 WO2005056752A2 (fr) 2003-10-24 2004-10-25 Procedes et compositions permettant de distribuer des polynucleotides

Country Status (8)

Country Link
US (2) US8039587B2 (fr)
EP (2) EP1687017B1 (fr)
JP (2) JP4838722B2 (fr)
AU (2) AU2004297533B2 (fr)
CA (1) CA2543257C (fr)
ES (1) ES2411962T3 (fr)
HK (1) HK1095738A1 (fr)
WO (1) WO2005056752A2 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511600A (ja) * 2005-10-14 2009-03-19 エムディーアールエヌエー，インコーポレイテッド Ｒｎａ治療用ペプチドリボ核酸縮合体粒子のための化合物及び方法
JP2010501175A (ja) * 2007-04-13 2010-01-21 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
WO2010045335A1 (fr) * 2008-10-16 2010-04-22 Gencia Corporation Polypeptides transducteurs pour modification du métabolisme mitochondrial
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US8232060B2 (en) 2006-04-14 2012-07-31 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US8278428B2 (en) 2007-02-16 2012-10-02 John Guy Mitochondrial nucleic acid delivery systems
WO2013188874A1 (fr) * 2012-06-15 2013-12-19 Gencia Corporation Méthodes atténuant les effets secondaires de la radiothérapie et de la chimiothérapie
US20150202154A1 (en) * 2010-04-21 2015-07-23 National University Corporation Hokkaido University Lipid membrane structure having intranuclear migrating property
US9840540B2 (en) 2012-11-19 2017-12-12 Japan Science And Technology Agency Artificial bioparticle and method of manufacturing the same
US10551383B2 (en) 2010-08-06 2020-02-04 Cell Signaling Technology, Inc. Methods of detecting a polypeptide having anaplastic lymphoma kinase activity in kidney cancer
CN113832111A (zh) * 2020-06-23 2021-12-24 南京大学 一种类外泌体技术用于制备新型溶瘤病毒的方法

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2530248A1 (fr) * 2003-06-25 2005-01-06 Gencia Corporation Vecteurs modifies pour la transfection d'organite
ES2411962T3 (es) 2003-10-24 2013-07-09 Gencia Corporation Métodos y composiciones para suministrar polinucleótidos
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
EP2145957B1 (fr) * 2004-04-20 2013-12-25 Marina Biotech, Inc. Compositions pour améliorer la fourniture d'ARN à double brin pour réguler l'expression des gènes dans des cellules de mammifères
US20060035815A1 (en) * 2004-05-04 2006-02-16 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
AU2006287481A1 (en) * 2005-09-08 2007-03-15 Mdrna, Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
CA2638915A1 (fr) * 2006-02-10 2007-08-23 The Regents Of The University Of California Livraison transductrice d'arnsi par liaison arn double brin de domaines de fusion au ptd/cpps
US20070281900A1 (en) * 2006-05-05 2007-12-06 Nastech Pharmaceutical Company Inc. COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
US20070275923A1 (en) * 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
CN101506368B (zh) * 2006-07-12 2017-02-08 加利福尼亚大学董事会 通过可逆的磷酸三酯电荷中和保护基转导运输核酸
WO2008038766A1 (fr) * 2006-09-29 2008-04-03 National University Corporation Gunma University Peptide fonctionnel présentant une activité de stimulation des cellules immunitaires
WO2008153725A2 (fr) 2007-05-25 2008-12-18 North Carolina State University Plate-forme pour l'apport, ciblé sur des cellules, de nanoparticules virales
JP2010537632A (ja) * 2007-08-29 2010-12-09 タフツ ユニバーシティー 組織及び細胞への核酸、タンパク質、薬物、及びアデノウイルスの送達を向上させるための細胞透過性ペプチドの製造及び使用方法、組成物並びにキット
EP2071027B1 (fr) * 2007-12-12 2011-10-26 Mitogenomix GmbH Procédé pour la génération de cellules Rho°
WO2010129853A2 (fr) 2009-05-07 2010-11-11 The Regents Of The University Of California Administration transductible d'acides nucléiques à l'aide de domaines de liaison à un arn double brin modifiés
JP5906184B2 (ja) 2009-06-22 2016-04-20 バーナム インスティテュート フォー メディカル リサーチ Ｃ末端エレメントを有するペプチドおよびタンパク質を使用する方法および組成物
WO2012051306A2 (fr) 2010-10-12 2012-04-19 Gencia Corporation Compositions et procédés pour moduler les protéases mitochondriales
WO2012118778A1 (fr) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Peptides car tronqués, procédés et compositions les utilisant
EP2715291A4 (fr) 2011-05-31 2015-10-21 Airware Inc Réétalonnage de capteurs de gaz non dispersif à absorption dans l'infrarouge (ndir) sollicités par absorption
WO2013016810A1 (fr) * 2011-08-04 2013-02-07 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Nanovecteurs ciblant des organelles
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
AU2012312654B2 (en) 2011-09-19 2017-04-13 Gencia Corporation Modified creatine compounds
WO2013103972A1 (fr) 2012-01-06 2013-07-11 Gencia Corporation Traitement du syndrome de la fragilité des personnes âgées et symptômes associés
WO2013142167A1 (fr) * 2012-03-20 2013-09-26 The University Of Iowa Research Foundation Glycoprotéine e2 du virus c de gb (virus de l'hépatite g) en tant qu'agent immunomodulateur
WO2013188873A1 (fr) 2012-06-15 2013-12-19 Gencia Corporation Compositions et procédés permettant d'améliorer les réponses immunitaires
CA2880869A1 (fr) 2012-08-20 2014-02-27 The Regents Of The University Of California Polynucleotides possedant des groupes bioreversibles
RU2015143130A (ru) 2013-03-15 2017-04-21 Дженсиа Корпорейшен Композиции и способы лечения состояний, поражающих эпидермис
WO2014144423A2 (fr) 2013-03-15 2014-09-18 Techulon Inc. Molécules antisens pour le traitement de l'infection à staphylococcus aureus
KR102206573B1 (ko) 2013-03-15 2021-01-25 테출론 인코포레이티드 스타필로코커스 아우레우스 감염의 치료를 위한 안티센스 분자
US10287331B2 (en) * 2013-04-15 2019-05-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Mitochondrial proteins constructs and uses thereof
EP3044314B1 (fr) 2013-07-12 2019-04-10 SeNa Research, Inc. Procédés et compositions d'interférence pour polymérase d'adn et synthèse d'adn
WO2015044704A1 (fr) * 2013-09-30 2015-04-02 Sanofi Utilisation d'un agoniste de neuroglobuline pour prévenir ou traiter des maladies mitochondriales dues à une déficience de rcciii et/ou rcci
CN104630149B (zh) * 2013-11-08 2018-08-21 中国科学院广州生物医药与健康研究院 外源线粒体导入到哺乳动物细胞中的方法
EP3105254B1 (fr) * 2014-02-14 2019-11-20 Symvivo Corporation Protéines hybrides et leurs utilisations
WO2016179138A1 (fr) * 2015-05-03 2016-11-10 The Regents Of The University Of Colorado Compositions de propionyl-coa carboxylase et utilisations de celles-ci
CN104945491A (zh) * 2015-07-01 2015-09-30 扬州大学 一个叶绿体发育必需的蛋白质及其基因和应用
US20190117799A1 (en) 2016-04-01 2019-04-25 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
WO2017221271A1 (fr) * 2016-06-22 2017-12-28 Indian Institute Of Technology Delhi Nanovecteur de ciblage d'organite
US11981703B2 (en) 2016-08-17 2024-05-14 Sirius Therapeutics, Inc. Polynucleotide constructs
JP6661797B2 (ja) * 2016-11-22 2020-03-11 株式会社東芝 核酸凝縮ペプチド、核酸凝縮ペプチドセット、核酸送達キャリア、核酸送達方法、細胞作製方法、細胞検出方法及びキット
US20200085758A1 (en) 2016-12-16 2020-03-19 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
WO2018204392A1 (fr) 2017-05-02 2018-11-08 Stanford Burnham Prebys Medical Discovery Institute Peptide liant des monocytes/macrophages associés à une tumeur et procédés d'utilisation associés
WO2018227112A1 (fr) 2017-06-09 2018-12-13 The Trustees Of Columbia University In The City Of New York Oligomères tat courts pour l'administration de médicaments
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
CA3122080A1 (fr) * 2018-12-06 2020-06-11 Arcturus Therapeutics, Inc. Compositions et methodes pour traiter une deficience en ornithine transcarbamylase
US20220119450A1 (en) 2019-02-04 2022-04-21 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
CN111034736B (zh) * 2019-12-13 2021-04-06 西北农林科技大学 一种杀虫组合物及其应用
WO2023056450A1 (fr) 2021-09-30 2023-04-06 Yale University Compositions et méthodes pour le traitement de la polykystose rénale autosomique dominante et d'autres maladies ayant une activité de mtor régulée à la hausse
WO2023211896A1 (fr) * 2022-04-26 2023-11-02 The General Hospital Corporation Systèmes génétiquement codés pour générer de l'oxygène dans des cellules eucaryotes vivantes
WO2024042466A1 (fr) 2022-08-22 2024-02-29 University Of Tartu Peptides pénétrant dans le cerveau et leurs procédés d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19856052A1 (de) 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen

Family Cites Families (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US580445A (en) * 1897-04-13 Motor-engine
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4622302A (en) 1984-08-09 1986-11-11 American National Red Cross Process for inducing membrane fusion under an electric field
US4752473A (en) 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US4873089A (en) 1985-07-12 1989-10-10 Cornell Research Foundation Inc., Cornell University Proteoliposomes as drug carriers
EP0257362A1 (fr) 1986-08-27 1988-03-02 Siemens Aktiengesellschaft Additionneur
US4803072A (en) 1986-09-10 1989-02-07 Smithkline Beckman Corporation Immunomodulation
US5149782A (en) 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
US6306625B1 (en) 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
JPH04222599A (ja) 1990-04-20 1992-08-12 Syntex Usa Inc 二重受容体ポリヌクレオチド検定方法
US5709879A (en) 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
US5985318A (en) 1990-08-24 1999-11-16 Burroughs Wellcome Co. Fusogenic liposomes that are free of active neuraminidase
EP0474247B1 (fr) 1990-09-07 1998-12-16 Nec Corporation Circuit de détermination du montant de décalage dans une calculation à virgule flottante utilisant peu de matériel et étant opérable à grande vitesse
US5756041A (en) 1991-07-11 1998-05-26 Arruda; William C. Method and apparatus for processing blown tube films
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5981273A (en) 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
US5780444A (en) 1991-12-13 1998-07-14 Trustees Of Princeton University Compositions and methods for cell transformation
US5422277A (en) 1992-03-27 1995-06-06 Ortho Diagnostic Systems Inc. Cell fixative composition and method of staining cells without destroying the cell surface
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US6080791A (en) 1992-07-24 2000-06-27 Seres Laboratories, Inc. Method of treating a viral condition by inhibiting membrane fusion
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
EP0670905B1 (fr) 1992-09-22 2003-07-23 Biofocus Discovery Limited Virus recombines presentant un polypeptide non-viral sur leur surface externe
US5552155A (en) 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
US5888981A (en) 1993-06-14 1999-03-30 Basf Aktiengesellschaft Methods for regulating gene expression
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
AU684524B2 (en) 1993-06-14 1997-12-18 Tet Systems Holding Gmbh & Co. Kg Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
US5859310A (en) 1993-06-14 1999-01-12 Basf Aktiengesellschaft Mice transgenic for a tetracycline-controlled transcriptional activator
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
US20030022315A1 (en) 1993-06-14 2003-01-30 Basf Aktiengesellschaft And Knoll Aktiengesellschaft Tetracycline-inducible transcriptional inhibitor fusion proteins
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5789156A (en) 1993-06-14 1998-08-04 Basf Ag Tetracycline-regulated transcriptional inhibitors
US5912411A (en) 1993-06-14 1999-06-15 University Of Heidelberg Mice transgenic for a tetracycline-inducible transcriptional activator
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
GB9317380D0 (en) 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
DE4335025A1 (de) 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
WO1995031183A1 (fr) 1994-05-16 1995-11-23 Washington University Composition et procede de fusion avec la membrane cellulaire
US5728399A (en) 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5799515A (en) 1995-02-17 1998-09-01 Floyd; Herbert R. Auto column pivot lock
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
US5723319A (en) 1995-06-05 1998-03-03 Avid Therapeutics, Inc. Cultured cell line that inducibly expresses the hepatitis B virus genome, and uses thereof for screening antiviral substances
US5851796A (en) 1995-06-07 1998-12-22 Yale University Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes
US5908777A (en) 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
US6017734A (en) 1995-07-07 2000-01-25 The Texas A & M University System Unique nucleotide and amino acid sequence and uses thereof
GB9515356D0 (en) 1995-07-26 1995-09-20 Medical Res Council Improvements in or relating to delivery of nucleic acid
CA2202928A1 (fr) 1995-08-17 1997-02-27 Wilhelmus Everhardus Hennink Poly(organo)phosphazenes utilisables dans des systemes de transfection de synthese
ES2242198T3 (es) 1995-10-25 2005-11-01 Octoplus B.V. Poliacrilatos y poli(alquil) acrilatos cationicos o las correspondientes acrilamidas para utilizar en sistemas de transfeccion sinteticos.
US5804445A (en) 1996-01-11 1998-09-08 Board Of Regents, The University Of Texas System High affinity mutants of nuclear factor-interleukin 6 and methods of use therefor
EP0888046A4 (fr) 1996-01-29 2001-10-04 Paik Kye Hyung Procede de production de proteine au moyen d'un systeme de traduction mitochondrique
US6037348A (en) 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
RU2066552C1 (ru) 1996-02-12 1996-09-20 Товарищество с ограниченной ответственностью "Био Прогресс" Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
US5770414A (en) 1996-02-20 1998-06-23 The Regents Of The University Of California Regulatable retrovirus system for genetic modification of cells
EP0902682A2 (fr) 1996-05-08 1999-03-24 Nika Health Products Limited Virosomes cationiques en tant que systeme d'apport de materiel genetique
US6004808A (en) 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
US5948681A (en) 1996-08-14 1999-09-07 Children's Hospital Of Philadelphia Non-viral vehicles for use in gene transfer
US6025192A (en) 1996-09-20 2000-02-15 Cold Spring Harbor Laboratory Modified retroviral vectors
US6255071B1 (en) 1996-09-20 2001-07-03 Cold Spring Harbor Laboratory Mammalian viral vectors and their uses
US5854016A (en) 1996-09-27 1998-12-29 Icos Corporation Creba Isoform
WO1998016199A1 (fr) 1996-10-15 1998-04-23 The Liposome Company, Inc. Administration de medicament a travers des liposomes contenant un n-acyl-phosphatidylethanolamine
US20020155095A1 (en) 1996-10-18 2002-10-24 Tattanahalli L. Nagabhushan Methods and compositions for delivery and expression of interferon-a nucleic acids
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5831020A (en) 1997-03-25 1998-11-03 The Research Foundation Of State University Of New York Protein-mediated nuclear import of DNA
US6368821B1 (en) 1997-04-14 2002-04-09 Stratagene Process for infecting eukaryotic cells with a bacterial virus
US6099847A (en) 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
GB9711115D0 (en) 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
US6127159A (en) * 1997-06-06 2000-10-03 The Board Of Trustees Of The Leland Stanford Junior University Mitofusin genes and their uses
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US7811803B2 (en) 1997-06-19 2010-10-12 University Of Medicine And Dentistry Of New Jersey Methods and compositions for rapid purification of proteasomes and methods of use of components thereof
EP1005483B1 (fr) 1997-06-19 2004-10-27 University of Medicine and Dentistry of New Jersey Procedes et compositions pour la purification rapide de proteasomes et procedes d'utilisation des composants de ces proteasomes
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US6087166A (en) 1997-07-03 2000-07-11 Basf Aktiengesellschaft Transcriptional activators with graded transactivation potential
FR2766195A1 (fr) 1997-07-21 1999-01-22 Transgene Sa Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charges negative, notamment des acides nucleiques, et leur utilisation en therapie genique
US6207648B1 (en) 1997-07-24 2001-03-27 Trustees Of Boston University Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
WO1999013905A1 (fr) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Mutants de poche de fixation de recepteur d'hemagglutinine de virus de grippe a
GB9720148D0 (en) 1997-09-22 1997-11-26 Innes John Centre Innov Ltd Gene silencing materials and methods
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US6136536A (en) 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
US5968773A (en) 1997-11-14 1999-10-19 Heddle; John A. System and method for regulation of gene expression
IT1297090B1 (it) 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
CA2314267A1 (fr) * 1997-12-10 1999-06-17 Washington University Systeme anti-pathogene et procedes d'utilisation
US6267987B1 (en) 1997-12-12 2001-07-31 Samyang Corporation Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake
CN1281355A (zh) 1997-12-12 2001-01-24 三阳株式会社 用于基因递送的生物可降解性混合聚合胶束
US6410057B1 (en) 1997-12-12 2002-06-25 Samyang Corporation Biodegradable mixed polymeric micelles for drug delivery
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6372720B1 (en) 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
WO1999042091A2 (fr) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Compositions d'apport dans des cellules
US6737506B1 (en) 1998-02-25 2004-05-18 Paul Anziano Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
US6986902B1 (en) 1998-04-28 2006-01-17 Inex Pharmaceuticals Corporation Polyanionic polymers which enhance fusogenicity
US6221665B1 (en) 1998-06-10 2001-04-24 University Of South Florida Electrofusion chamber
US6143564A (en) 1998-07-07 2000-11-07 University Of Hawaii Use of the polar body chromosomes for the production of embryos and normal offspring
US6759236B1 (en) 1998-08-18 2004-07-06 Research Development Foundation Methods to enhance and confine expression of genes
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
AU5779499A (en) 1998-08-28 2000-03-21 Pioneer Hi-Bred International, Inc. Organelle targeting sequences
WO2000023568A2 (fr) 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Procedes et compositions permettant de reduire la surproduction de mitochondries des especes oxygene reactives dans les cellules
US6759574B1 (en) 1998-11-05 2004-07-06 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Plants having enhanced gall resistance and methods and compositions for producing same
US20050037335A1 (en) 1998-11-07 2005-02-17 Wolfgang Hillen Method for identifying novel transcriptional regulatory proteins
ATE476513T1 (de) 1998-12-22 2010-08-15 Dow Agrosciences Llc Verfahren zum limitieren des herauskreuzens und unerwünschten genflusses in nutzpflanzen
US6903077B1 (en) 1999-01-04 2005-06-07 University Of Vermont And State Agricultural College Methods and products for delivering nucleic acids
DE19900743A1 (de) 1999-01-12 2000-07-13 Aventis Pharma Gmbh Neue komplexbildende Proteine
US6323391B1 (en) 1999-01-25 2001-11-27 Trustees Of The University Of Pennsylvania Methods and transgenic mouse model for identifying and modulating factors leading to motor neuron degeneration
EP1165819A2 (fr) * 1999-03-31 2002-01-02 Invitrogen Corporation Diffusion de sequences de proteines fonctionnelles par translocation de polypeptides
US6849272B1 (en) 1999-04-21 2005-02-01 Massachusetts Institute Of Technology Endosomolytic agents and cell delivery systems
ATE368122T1 (de) 1999-04-29 2007-08-15 Cell Genesys Inc Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer
AU761591B2 (en) 1999-05-17 2003-06-05 Conjuchem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
JP4106402B2 (ja) 1999-05-21 2008-06-25 フジコピアン株式会社 熱転写画像形成方法およびそれに用いる熱転写材の組み合わせ
US7319086B1 (en) 1999-05-28 2008-01-15 University Of Sydney Method of prophylaxis and treatment and agents useful for same
DE60043889D1 (en) 1999-06-07 2010-04-08 Tet Systems Holding Gmbh & Co Tet repressor basierte transkriptionale regulatorische proteine
CA2272788A1 (fr) 1999-06-11 2000-12-11 Garching Innovation Gmbh Moyens et methodes pour transformer les mitochondries des vegetaux
US6770632B1 (en) 1999-07-16 2004-08-03 The General Hospital Corporation Folypolyglutamyl synthetase gene transfer to enhance antifolate
US6586411B1 (en) 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
US6632800B1 (en) 1999-08-17 2003-10-14 Mayo Foundation For Medical Education And Research System for monitoring the expression of transgenes
US6780639B1 (en) 1999-08-24 2004-08-24 Universite Libre De Bruxelles Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization
ES2277854T5 (es) 1999-08-25 2011-02-04 Allergan, Inc. Neurotoxinas recombinantes activables.
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
WO2001017511A1 (fr) 1999-09-03 2001-03-15 Chugai Seiyaku Kabushiki Kaisha Procede de liberation intracellulaire prolongee de medicaments et de preparations
US6633933B1 (en) 1999-09-30 2003-10-14 Oak Technology, Inc. Controller for ATAPI mode operation and ATAPI driven universal serial bus mode operation and methods for making the same
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US20040072739A1 (en) 1999-11-10 2004-04-15 Anderson Christen M. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
US6867036B1 (en) 1999-11-23 2005-03-15 Mayo Foundation For Medical Education And Research Gene expression by positive feedback activation of a cell type-specific promoter
US7060291B1 (en) 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
DE10003241A1 (de) 2000-01-26 2001-08-02 Werner Lubitz Verschließen von Bakterienghosts
US6872406B2 (en) 2000-02-11 2005-03-29 Children's Hospital Research Foundation Fusogenic properties of saposin C and related proteins and polypeptides for application to transmembrane drug delivery systems
PL357084A1 (en) 2000-02-21 2004-07-12 Fujisawa Pharmaceutical Co, Ltd. Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
EP2345742B1 (fr) 2000-03-30 2014-06-11 The Whitehead Institute for Biomedical Research Médiateurs spécifiques de la séquence d'ARN d'interférence d'ARN
CA2407460C (fr) 2000-04-28 2013-06-25 Sangamo Biosciences, Inc. Modification ciblee de la structure de chromatine
US20020151028A1 (en) 2000-05-18 2002-10-17 Cornell Research Foundation, Inc. Structure-based drug design for Ulp1 protease substrates
US7244560B2 (en) 2000-05-21 2007-07-17 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US20020031818A1 (en) 2000-06-22 2002-03-14 Ronai Ze?Apos;Ev A. Modification of Mdm2 activity
GB0027328D0 (en) 2000-06-23 2000-12-27 Aventis Pharma Inc Bioengineered vehicles for targeted nucleic acid delivery
CA2416664A1 (fr) 2000-07-21 2002-01-31 Syngenta Participations Ag Code de reconnaissance pour domaines en doigt de zinc et ses utilisations
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
GB0027905D0 (en) 2000-11-15 2000-12-27 Glaxo Group Ltd New protein
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US6771623B2 (en) 2000-12-01 2004-08-03 Telefonaktiebolaget Lm Ericsson (Publ) Method for ensuring reliable mobile IP service
DE10290072D2 (de) 2001-01-10 2003-12-18 Amaxa Gmbh Modulare Transfektionssysteme
US6897196B1 (en) 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
GB0106315D0 (en) 2001-03-14 2001-05-02 Ich Productions Ltd Transfection complexes
JP2002368577A (ja) 2001-04-06 2002-12-20 Murata Mfg Co Ltd 二重モードフィルタ
CA2445049A1 (fr) 2001-05-04 2002-11-14 Cornell Research Foundation, Inc. Systeme d'expression de proteine sumo a scission rapide pour proteines difficiles a exprimer
DE60216151T2 (de) 2001-05-31 2007-09-27 ConjuChem Biotechnologies Inc., Montreal Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
US7314971B2 (en) 2001-07-12 2008-01-01 Basf Plant Science Gmbh Nuclear fertility restorer genes and methods of use in plants
KR100495138B1 (ko) 2001-07-31 2005-06-14 학교법인 한림대학교 식물세포 투과 도메인-화물분자 복합체
DE10143205A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Verfahren zur Proteinproduktion in Pflanzen
AU2002329034A1 (en) 2001-09-17 2003-04-01 Yeda Research And Development Co. Ltd. Nucleic acid constructs for the delivery of polynucleotides into dna-containing organelles,and uses thereof
ATE392216T1 (de) 2001-11-14 2008-05-15 Novavax Inc Mycobakterieller impfstoff
US7750134B2 (en) 2001-11-20 2010-07-06 Sanford-Burnham Medical Research Institute Nucleic acids encoding microbial SUMO protease homologs
US7018819B2 (en) 2001-11-30 2006-03-28 Cellectricon Ab Method and apparatus for manipulation of cells and cell-like structures focused electric fields in microfludic systems and use thereof
DK1463836T3 (da) 2001-12-13 2010-01-18 Univ Virginia Vektormedieret organeltransfektion
US20030186281A1 (en) 2001-12-21 2003-10-02 Wolfgang Hillen Modified tetracycline repressor protein compositions and methods of use
JP2005514025A (ja) 2002-01-07 2005-05-19 ライフセンサーズ、インク． タンパク質発現及び精製のための方法及び組成
US7220576B2 (en) 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
WO2003076561A2 (fr) 2002-03-09 2003-09-18 Artemis Pharmaceuticals Gmbh Proteine de fusion a recombinase presentant un apport cellulaire ameliore
US7919075B1 (en) 2002-03-20 2011-04-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
EP1495045B1 (fr) 2002-03-29 2009-09-02 Creagene, Inc. Peptides de transduction cytoplasmiques et leurs utilisations
WO2003087768A2 (fr) 2002-04-12 2003-10-23 Mitokor Cibles pour une intervention therapeutique identifiee dans le proteome mitochondrial
WO2003087162A2 (fr) 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides et procedes utilises dans la detection et le traitement du cancer
EP1501532A4 (fr) 2002-04-22 2007-11-14 Univ Leland Stanford Junior Inhibiteurs peptidiques de la proteine kinase c
JP4448440B2 (ja) 2002-04-30 2010-04-07 株式会社ディナベック研究所 プロテアーゼ依存性トロピズムが改変されたベクター
US6835810B2 (en) 2002-05-13 2004-12-28 Geneshuttle Biopharma, Inc. Fusion protein for use as vector
US7056529B2 (en) 2002-05-14 2006-06-06 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
US7273620B1 (en) 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
MXPA04011679A (es) 2002-05-29 2005-03-07 Regeneron Pharma Sistema de expresion eucariotico inducible.
US7553667B2 (en) 2002-06-06 2009-06-30 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Regulation of gene expression using chromatin remodelling factors
US7105347B2 (en) 2002-07-30 2006-09-12 Corning Incorporated Method and device for protein delivery into cells
US7371922B2 (en) 2002-07-31 2008-05-13 The Board Of Trustees Of The University Of Illinois Nuclear transfer with porcine embryonic stem cells
US6850133B2 (en) 2002-08-14 2005-02-01 Intel Corporation Electrode configuration in a MEMS switch
DE10238046A1 (de) 2002-08-20 2004-03-04 Giesing, Michael, Prof. Dr.med. Verfahren zum Untersuchen von Körperflüssigkeiten auf Krebszellen, dessen Verwendung, entsprechende Analysekits und Verwendung bestimmter Wirkstoffe zur Behandlung von Krebs
WO2004020645A2 (fr) 2002-08-28 2004-03-11 Universität Heidelberg Loci chromosomiques pour le controle strict des activites geniques au moyen de systemes d'activation de transcription
US7042608B2 (en) 2002-09-18 2006-05-09 Pentax Corporation Scanning optical system
US7459145B2 (en) 2002-10-25 2008-12-02 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
US7376128B2 (en) 2002-10-25 2008-05-20 Utstarcom (China) Co., Ltd. Method and system for voice handling via dynamic home agents in a network employing all-IP architecture
KR100472938B1 (ko) 2002-10-31 2005-03-11 학교법인 한림대학교 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도
CN100488491C (zh) 2002-11-21 2009-05-20 派维翁生物技术有限公司 高效融合小泡,其制备方法和含有该小泡的药物组合物
US7579515B2 (en) 2002-12-24 2009-08-25 North Carolina State University Increasing gamete production with a gene switch
CA2512512A1 (fr) 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Utilisations de proteines de liaison a l'adn
JP2006517790A (ja) * 2003-01-09 2006-08-03 インヴィトロジェン コーポレーション ポリペプチド−核酸複合体の細胞の送達および活性化
US7090837B2 (en) 2003-01-21 2006-08-15 The Salk Institute For Biological Studies Compositions and methods for tissue specific targeting of lentivirus vectors
US7402409B2 (en) 2003-01-23 2008-07-22 Epitomics, Inc. Cell fusion method
US6878374B2 (en) 2003-02-25 2005-04-12 Nitto Denko Corporation Biodegradable polyacetals
US7560264B2 (en) 2003-03-14 2009-07-14 Brookhaven Science Associates, Llc High density growth of T7 expression strains with auto-induction option
US8399217B2 (en) 2003-03-14 2013-03-19 Brookhaven Science Associates, Llc High density growth of T7 expression strains with auto-induction option
JP2007525456A (ja) 2003-05-15 2007-09-06 ザ・ボード・オブ・リージェンツ・フォー・オクラホマ・ステート・ユニバーシティ ウマ２型インフルエンザウイルスのｈａ１を発現するｄｎａワクチン
GB0313132D0 (en) 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
WO2005003766A2 (fr) 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Procedes de regulation du metabolisme et de la fonction mitochondriale
EP1732581A4 (fr) 2003-06-20 2008-06-04 Univ California San Diego Transduction polypeptidique et peptides fusogenes
CA2530248A1 (fr) * 2003-06-25 2005-01-06 Gencia Corporation Vecteurs modifies pour la transfection d'organite
US7655413B2 (en) 2003-06-26 2010-02-02 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
WO2005003315A2 (fr) * 2003-07-01 2005-01-13 Allele Biotechnology & Pharmaceuticals, Inc. Compositions et methodes pour la transfection assistee par peptide
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US7048925B2 (en) 2003-08-28 2006-05-23 Nitto Denko Corporation Acid-sensitive polyacetals and methods
JP2005108515A (ja) 2003-09-29 2005-04-21 Sanyo Electric Co Ltd 非水電解質電池
ES2411962T3 (es) 2003-10-24 2013-07-09 Gencia Corporation Métodos y composiciones para suministrar polinucleótidos
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US20090208478A1 (en) 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8283444B2 (en) 2003-10-24 2012-10-09 Wake Forest University Non-viral delivery of compounds to mitochondria
CA2554735A1 (fr) 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Molecules porteuses et therapeutiques
WO2005090390A1 (fr) 2004-03-17 2005-09-29 Crucell Holland B.V. Nouveau dosage pour separer et quantifier des antigenes d'hemagglutinine
DE602004023238D1 (de) 2004-05-11 2009-10-29 Shukokai Inc Methoden zur Kultivierung von Antigen presentierenden Immunzellen
CA2570959C (fr) 2004-06-21 2014-09-30 Progenra Inc. Methode de diagnostic et de criblage, et trousses associees a une activite proteolytique
DK1634955T3 (da) 2004-09-14 2008-03-17 Gsf Forschungszentrum Umwelt Konditionale genvektorer, der er reguleret i cis
JP4959570B2 (ja) 2004-10-18 2012-06-27 日東電工株式会社 細胞内ペプチド送達
US7829104B2 (en) 2004-12-01 2010-11-09 Aeras Global Tb Vaccine Foundation Electroporation of Mycobacterium and overexpression of antigens in mycobacteria
FR2878846B1 (fr) 2004-12-07 2007-02-23 Enscr Composes analogues de lipides membranaires d'archaebacteries et compositions liposomiales integrant de tel composes
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
WO2006073976A2 (fr) 2004-12-30 2006-07-13 Lifesensors, Inc. Compositions, procedes et kits permettant d'ameliorer l'expression, la solubilite et l'isolation des proteines
US7741431B2 (en) 2005-02-01 2010-06-22 The United States Of America As Represented By The Secretary Of The Army Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
US7566454B2 (en) 2005-02-24 2009-07-28 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
MX2007010561A (es) 2005-03-15 2008-02-22 Nycomed Gmbh N-sulfonilpirroles y su uso como inhibidores de la histona desacetilasa.
JP2008532549A (ja) 2005-03-15 2008-08-21 アラーガン、インコーポレイテッド 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素
US7881468B2 (en) 2005-04-08 2011-02-01 Telefonaktiebolaget L M Ericsson (Publ) Secret authentication key setup in mobile IPv6
US8114581B2 (en) 2005-09-15 2012-02-14 The Regents Of The University Of California Methods and compositions for detecting neoplastic cells
CA2630348C (fr) 2005-11-17 2016-01-12 Stichting Voor De Technische Wetenschappen Systemes d'expression inductible
ES2325644B1 (es) 2005-12-30 2010-06-28 Universidad Del Pais Vasco (Upv/Ehu) Hexapeptidos no proteolizables inhibidores de la glicoproteina 41 del virus del sida.
CA2638915A1 (fr) 2006-02-10 2007-08-23 The Regents Of The University Of California Livraison transductrice d'arnsi par liaison arn double brin de domaines de fusion au ptd/cpps
US7807363B2 (en) 2006-02-28 2010-10-05 Alcon Research, Ltd. Superoxide dismutase-2 expression for glaucoma diagnosis
US7795380B2 (en) 2006-06-02 2010-09-14 University Of Iowa Research Foundation Compositions and methods for nucleic acid delivery
EP2038298A2 (fr) 2006-07-11 2009-03-25 Allergan, Inc. Toxines clostridiennes modifiées à capacité de translocation améliorée et à activité modifiée de ciblage des cellules cibles des toxines clostridiennes
WO2008140582A2 (fr) 2006-11-22 2008-11-20 Emory University Production de peptides anti-microbiens
US7989185B2 (en) 2006-11-29 2011-08-02 The Board Of Trustees Of The Leland Stanford Junior University Rapid, informative diagnostic assay for influenza viruses including H5N1
WO2008072781A1 (fr) 2006-12-12 2008-06-19 Kyushu University, National University Corporation Procédé de prévention ou de traitement d'un trouble de la mémoire chez un mammifère
TWI328040B (en) 2007-05-04 2010-08-01 Stresspro Biomedicine Inc Expression system of recombinant proteins with enhanced yield and immunogenecity
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
AR069704A1 (es) 2007-12-18 2010-02-10 Alcon Res Ltd Sistema de administracion de rnai de interferencia y usos del mismo
EP2100961A1 (fr) 2008-03-04 2009-09-16 Icon Genetics GmbH Procédé de production de protéase dans les plantes
US8103278B2 (en) 2008-04-01 2012-01-24 Mediatek Inc. Method and system for managing idle mode of a mobile node with multiple interfaces
TW200951219A (en) 2008-05-06 2009-12-16 Academia Sinica An improved SUMO fusion protein system for effective production of native proteins
TW200948959A (en) 2008-05-06 2009-12-01 Academia Sinica Preparation of soluble capsid proteins of picornavirus using SUMO fusion technology
CN101307316B (zh) 2008-07-22 2011-03-16 北京中农颖泰生物技术有限公司 抗菌肽cad在枯草杆菌中的分泌表达及重组枯草杆菌表达系统
US8440449B2 (en) 2008-09-30 2013-05-14 The United States Of America, As Represented By The Secretary Of Agriculture Transformed Saccharomyces cerevisiae engineered for xylose utilization
JP5576382B2 (ja) 2008-10-01 2014-08-20 テット・システムズ・ゲーエムベーハー・ウント・カンパニー・カーゲー テトラサイクリン誘導可能な転写制御配列
US8007786B2 (en) 2009-10-20 2011-08-30 Asi Agenzia Spaziale Italiana Radioprotective SOD soluble isoform and uses thereof
KR20120115976A (ko) 2009-12-07 2012-10-19 시냅틱 리서치, 엘엘씨 프로테아제 활성 저해제의 동정 방법 및 프로테아제 활성의 존재 분석 방법
US8697376B2 (en) 2010-02-03 2014-04-15 Lifesensors, Inc. Synthetic protease substrates, assay methods using such substrates and kits for practicing the assay

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19856052A1 (de) 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATSUHIMA ET AL., J. BIOL. CHEM., vol. 278, no. 33, 2003, pages 31149 - 31158
See also references of EP1687017A4

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
JP2016073290A (ja) * 2005-10-14 2016-05-12 マリーナ バイオテック，インコーポレイテッド Ｒｎａ治療用ペプチドリボ核酸縮合体粒子のための化合物及び方法
JP2014110796A (ja) * 2005-10-14 2014-06-19 Marina Biotech Inc Ｒｎａ治療用ペプチドリボ核酸縮合体粒子のための化合物及び方法
JP2009511600A (ja) * 2005-10-14 2009-03-19 エムディーアールエヌエー，インコーポレイテッド Ｒｎａ治療用ペプチドリボ核酸縮合体粒子のための化合物及び方法
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US9988688B2 (en) 2006-04-14 2018-06-05 Cell Signaling Technology, Inc. Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
US8232060B2 (en) 2006-04-14 2012-07-31 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US11505833B2 (en) 2006-04-14 2022-11-22 Cell Signaling Technology, Inc. Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
US8288102B2 (en) 2006-04-14 2012-10-16 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US10955416B2 (en) 2006-04-14 2021-03-23 Cell Signaling Technology, Inc. Compositions for detecting mutant anaplastic lymphoma kinase in human lung cancer
US8377642B2 (en) 2006-04-14 2013-02-19 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US8481279B2 (en) 2006-04-14 2013-07-09 Cell Signaling Technology, Inc. Methods of treating lung cancer using inhibitors anaplastic lymphoma kinase
US8486645B2 (en) 2006-04-14 2013-07-16 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US10870892B2 (en) 2006-04-14 2020-12-22 Cell Signaling Technology, Inc. Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
US9523130B2 (en) 2006-04-14 2016-12-20 Cell Signaling Technology, Inc. Methods of treating non-small cell lung carcinoma (NSCLC)
AU2008216018B2 (en) * 2007-02-16 2012-10-25 John Guy Mitochondrial nucleic acid delivery systems
US8278428B2 (en) 2007-02-16 2012-10-02 John Guy Mitochondrial nucleic acid delivery systems
JP2010501175A (ja) * 2007-04-13 2010-01-21 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
WO2010045335A1 (fr) * 2008-10-16 2010-04-22 Gencia Corporation Polypeptides transducteurs pour modification du métabolisme mitochondrial
CN102245631A (zh) * 2008-10-16 2011-11-16 真希亚公司 用于改变线粒体代谢的可转导多肽
AU2009303382B2 (en) * 2008-10-16 2013-08-29 Gencia Corporation Transducible polypeptides for modifying mitochondrial metabolism
US20150202154A1 (en) * 2010-04-21 2015-07-23 National University Corporation Hokkaido University Lipid membrane structure having intranuclear migrating property
US10551383B2 (en) 2010-08-06 2020-02-04 Cell Signaling Technology, Inc. Methods of detecting a polypeptide having anaplastic lymphoma kinase activity in kidney cancer
WO2013188874A1 (fr) * 2012-06-15 2013-12-19 Gencia Corporation Méthodes atténuant les effets secondaires de la radiothérapie et de la chimiothérapie
US9840540B2 (en) 2012-11-19 2017-12-12 Japan Science And Technology Agency Artificial bioparticle and method of manufacturing the same
CN113832111A (zh) * 2020-06-23 2021-12-24 南京大学 一种类外泌体技术用于制备新型溶瘤病毒的方法

Also Published As

Publication number Publication date
JP2007508846A (ja) 2007-04-12
AU2010206037A1 (en) 2010-08-19
WO2005056752A3 (fr) 2005-09-29
US8541550B2 (en) 2013-09-24
JP4838722B2 (ja) 2011-12-14
EP1687017B1 (fr) 2013-03-06
CA2543257A1 (fr) 2005-06-23
JP2011137001A (ja) 2011-07-14
US8039587B2 (en) 2011-10-18
EP2418281A3 (fr) 2012-09-19
EP1687017A2 (fr) 2006-08-09
EP1687017A4 (fr) 2009-08-19
WO2005056752A9 (fr) 2009-07-23
US20110300600A1 (en) 2011-12-08
AU2004297533A1 (en) 2005-06-23
EP2418281A2 (fr) 2012-02-15
EP2418281B1 (fr) 2016-06-01
CA2543257C (fr) 2013-12-31
US20050147993A1 (en) 2005-07-07
ES2411962T3 (es) 2013-07-09
HK1095738A1 (en) 2007-05-18
AU2004297533B2 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
AU2004297533B2 (en) Methods and compositions for delivering polynucleotides
US8507277B2 (en) Nonviral vectors for delivering polynucleotides
AU2010236076B2 (en) Modified Vectors for Organelle Transfection
CN110291100B (zh) 用于将多肽负荷从细胞外空间递送至靶真核细胞的胞质溶胶和/或细胞核的合理设计的合成肽穿梭剂，其用途、与其相关的方法和试剂盒
US8927691B2 (en) Transducible polypeptides for modifying metabolism
US8952133B2 (en) Nonviral vectors for delivering polynucleotides to target tissue
US8062891B2 (en) Nonviral vectors for delivering polynucleotides to plants
EP1463836B1 (fr) Transfection d'organelle induite par un vecteur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004297533

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006536845

Country of ref document: JP

Ref document number: 2543257

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2004817807

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004297533

Country of ref document: AU

Date of ref document: 20041025

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004297533

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004817807

Country of ref document: EP